Method for expanding gamma delta t cells
By depleting αβ T cells and using anti-CD3 antibodies and IL-15 to culture γδ T cells, and performing exogenous nucleic acid transduction, the problem of poor amplification and cytotoxicity of γδ T cells in the prior art was solved, and solid tumors were achieved efficient killing and lasting therapeutic effects.
Patent Information
- Application Number
- CN202380030812.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-04
- Filing Date
- 2023-04-04
- Publication Date
- 2024-11-19
AI Technical Summary
Existing methods have limited activity against solid tumor targets when amplifying γδ T cells, and are difficult to achieve effective cytotoxic effects.
By depleting αβ T cells from a sample of a subject containing γδ T cells, γδ T cells rich in compositions were cultured in the absence of IL-4 using an anti-CD3 antibody or fragment thereof and IL-15 and exogenous nucleic acid Transduced to express chimeric antigen receptors, amplifying engineered γδ T cells.
The efficient expansion of γδT cells and significant cytotoxicity to solid tumors were achieved, with a persistence of cytotoxicity of at least 14 days, and the engineered γδT cells can continuously control tumor growth under multiple rounds of antigen stimulation.
Smart Images

Figure BDA0005061900970000491 
Figure HDA0005061900980000011 
Figure HDA0005061900980000021
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This PCT application claims the benefit of priority to UK application number 2204926.6 filed on April 4, 2022; the said application is incorporated herein by reference in its entirety. Field of the Invention
[0003] The present invention relates to methods for expanding γδT cells and optionally engineering the cells. The expanded and engineered γδT cells produced according to the methods described herein can be used to treat cancer, in particular solid tumors. The present invention also relates to individual cells and cell populations produced by the methods described herein. Background of the Invention
[0005] Gamma delta T cells (γδT cells) represent a subset of T cells that express a unique defined γδT cell receptor (TCR) on the surface. This TCR consists of a gamma (γ) chain and a delta (δ) chain. The human γδTCR chain is selected from three major δ chains Vδ1, Vδ2 and Vδ3 and six γ chains. Human γδT cells can be broadly classified based on their TCR chains because certain γ and δ types are more commonly (but not exclusively) present on cells in one or more tissue types. For example, most blood-resident γδT cells express Vδ2TCR, such as Vγ9Vδ2, but this is less common in tissue-resident γδT cells, which more often use Vδ1 in the skin and Vγ4 in the intestine.
[0006] Vδ1γδT cells are a subset of innate T cells defined by the expression of a T cell receptor consisting of a γ chain paired with a Vδ1 chain. In mice, Vδ1γδT cells are mainly tissue-resident, where they are highly protective against a wide spectrum of cancers by mediating anti-tumor responses through pattern and natural cytotoxicity receptor recognition. Similarly, in humans, Vδ1γδT cells reside primarily in epithelial tissues, mediate target cell recognition that is not MHC-restricted, and are not allogeneic HLA reactive. Therefore, γδT cell adoptive cell therapy does not require HLA matching of patients. The inherent Vδ1γδT cell biology that can achieve non-antigen-dependent tumor recognition, no HLA matching is necessary, and inherently migrates to and resides in human tissues makes Vδ1γδT cells an attractive platform for cell therapy.
[0007] Therefore, there is a need for methods to efficiently expand γδ T cells to allow their suitability as therapy, for example as adoptive T cell therapy, and methods with the potential to provide allogeneic 'off-the-shelf' chimeric antigen receptor-expressing γδ T cell therapy, such as for the treatment of solid tumors.
[0008] WO2015189356 describes a composition for amplifying lymphocytes obtained from a sample obtained by aphaeresis, the composition comprising at least two types of cytokines selected from IL-2, IL-15 and IL-21. WO2016198480 describes a method for amplifying Vδ2-TCRγδ+T cells, particularly those Vδ2-TCRγδ+T cells derived from a blood sample, using a two-step culture method, the two-step culture method being included in a first culture medium comprising T cell mitogens and interleukin-4 (IL-4) and then culturing cells in a second culture medium comprising T cell mitogens and interleukin-15 (IL-15). WO2016081518 describes a method for amplifying engineered and unengineered γδT cell populations using antibodies that bind to the δ chain of TCR.
[0009] While these disclosures are directed to solving the above problems to some extent, there is still a need for improved methods of expanding γδ T cells, particularly generating γδ T cells that effectively target solid tumors. Summary of the invention
[0010] According to a first aspect of the present invention, a method for expanding γδT cells is provided, wherein the method comprises the following steps:
[0011] (1) preparing a composition enriched in γδ T cells by depleting αβ T cells from a sample obtained from a subject containing γδ T cells;
[0012] (2) culturing the composition enriched in γδ T cells in the presence of:
[0013] (i) an anti-CD3 antibody or a fragment thereof; and
[0014] (ii) interleukin-15 (IL-15) in the absence of interleukin-4 (IL-4) from the first day of said culturing (e.g. wherein no IL-4 is added at all during said method); and
[0015] (3) Isolating a cell population cultured from the composition.
[0016] According to another aspect of the present invention, there is provided a method for engineering γδT cells, the method comprising the following steps:
[0017] (i) preparing a composition enriched for γδ T cells using a method as defined herein;
[0018] (ii) transducing the composition with an exogenous nucleic acid for expression in the γδ T cells; and
[0019] (iii) culturing the transduced composition to expand the engineered γδ T cells.
[0020] According to another aspect of the invention, there is provided an expanded population of γδ T cells obtainable (such as obtained) by a method as defined herein.
[0021] According to another aspect of the present invention, there is provided a pharmaceutical composition comprising an expanded γδ T cell population as defined herein.
[0022] According to another aspect of the present invention, there is provided an expanded γδ T cell population or a pharmaceutical composition as defined herein for use as a medicament.
[0023] According to another aspect of the present invention, there is provided an expanded γδ T cell population or a pharmaceutical composition as defined herein for use in treating cancer.
[0024] In some aspects, the expanded γδ T cells are capable of endocytotoxicity for at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, at least about 14 days, at least about 15 days, at least about 16 days, at least about 17 days, at least about 18 days, at least about 19 days, at least about 20 days, or at least about 21 days. In some aspects, the expanded γδ T cells are capable of endocytotoxicity for at least about 14 days. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1 The Method 1 and Method 2 amplification schemes described in the embodiments are illustrated in drawings.
[0026] Figure 2 The diagram shows the cell yield at harvest for cell products produced using either Method 1 or Method 2.
[0027] Figure 3 Schematic representation of the analysis of immune cell composition by flow cytometry.
[0028] Figure 4 Graph represents analysis of CD56 expression by flow cytometry in γδ T cell products generated by methods 1 or 2.
[0029] Figure 5 Graphs show comparison of cell surface marker expression in Vδ1 T cell products generated by method 1 or 2.
[0030] Figure 6 Graph showing comparison of chemokine receptor expression in Vδ1 T cell products generated by either method 1 or 2.
[0031] FIG. 7 is a diagram showing in-depth phenotypic analysis of cell products produced by methods 1 or 2. Fig. 7A Volcano plot showing differentially expressed cell surface markers between Vδ1 T cell products generated by method 1 or 2. Figure 7B Pie chart of top signaling pathways associated with significantly differentially expressed cell surface markers between Vδ1 T cell products generated by method 1 or 2.
[0032] FIG. 8A to FIG. 8C Graph showing comparison of secreted soluble factors in γδ T cell products generated by either method 1 or 2. Fig. 8A For the main component analysis, Figure 8B Comparison of the major secreted cytokines, and Figure 8C For comparison of chemokines.
[0033] Fig. 9 Graph showing total cell recovery and viability following cryopreservation of cell products generated using either Method 1 or 2.
[0034] Fig.10 Graph showing the cytotoxicity of cell products produced by methods 1 or 2 after cryopreservation against lung cancer cell lines (NCI-H226 and A549), gastric cancer cell line (GSU), colorectal cell line (HT-29), ovarian adenocarcinoma cell line (OvCAR3), skin cancer cell line (A375), and pancreatic cancer cell line (CAPAN2).
[0035] FIG. 11A to FIG. 11B Schematic representation of chimeric antigen receptor (CAR) expression in cell products produced by method 1 or 2. Fig.11A Comparison of CAR expression in cell products produced by method 1 or 2. Fig. 11B Representative flow cytometry plots of CAR expression in cell products produced by method 1 or 2 in one donor are shown.
[0036] Fig.12 Schematic representation of the functionality of CAR engineered cell products produced by methods 1 or 2 in cytotoxicity assays against ovarian adenocarcinoma cell lines (OvCAR3) and mesothelin-engineered lung cancer cell lines (A549-Meso).
[0037] FIG. 13A to FIG. 13B Schematic representation of tumor control and proliferation of CAR-engineered cell products produced by method 1 or 2 after repeated tumor stimulation. Fig.13A Shown is tumor control after repeated challenge every 3 / 4 days with OVCAR3 (top) or A549-Meso (bottom). Fig. 13B Illustration of CAR-engineered cell product expansion during repeated tumor challenge analysis using OVCAR3 (top) or A549-Meso (bottom). DETAILED DESCRIPTION
[0038] Methods for expanding γδT cells derived from hematopoietic samples, such as peripheral blood, have been described previously. However, while such methods provide γδT cells with demonstrated efficacy against a variety of hematological targets, limited activity has been shown against solid tumor targets. The present invention provides a simplified method for expanding γδT cells, particularly those derived from blood samples, that produces equivalent or better total cell fold expansion and surprising efficacy against solid malignancies.
[0039] Therefore, according to a first aspect of the present invention, a method for expanding γδ T cells is provided, wherein the method comprises the following steps:
[0040] (1) preparing a composition enriched in γδ T cells by depleting αβ T cells from a sample obtained from a subject containing γδ T cells;
[0041] (2) culturing the composition enriched in γδ T cells in the presence of:
[0042] (i) an anti-CD3 antibody or a fragment thereof; and
[0043] (ii) interleukin-15 (IL-15) in the absence of interleukin-4 (IL-4) from the first day of said culturing (e.g. wherein no IL-4 is added at all during said method); and
[0044] (3) Isolating a cell population cultured from the composition.
[0045] In certain embodiments, the sample (i.e., the starting sample) is a human sample. The present invention finds specific uses of γδT cells derived from blood or its fractions. It was unexpectedly found that the method of the present invention can expand γδT cells derived from hematological samples and has improved cytotoxicity against solid tumors.
[0046] Therefore, in one embodiment, the sample is a hematopoietic system sample or a fraction thereof. In another embodiment, the sample is selected from peripheral blood, umbilical cord blood, lymphoid tissue, thymus, bone marrow, spleen, lymph node tissue or a fraction thereof, in particular peripheral blood or a fraction thereof. In another embodiment, the sample is composed of peripheral blood mononuclear cells (PBMC) or low density mononuclear cells (LDMC).
[0047] In an alternative embodiment, the sample is non-hematopoietic tissue. "Non-hematopoietic tissue" or "non-hematopoietic tissue sample" mentioned herein includes skin (e.g., human skin) and intestinal tract (e.g., human intestinal tract). Non-hematopoietic tissue is tissue other than blood, bone marrow, or thymus tissue. In one embodiment, the non-hematopoietic tissue sample is skin (e.g., human skin). In another embodiment, the non-hematopoietic tissue sample is intestinal tract or gastrointestinal tract (e.g., human intestinal tract or human gastrointestinal tract). In some embodiments, the non-hematopoietic tissue sample is skin (e.g., human skin), which can be obtained by methods known in the art. Alternatively, the non-hematopoietic tissue sample is selected from: gastrointestinal tract (e.g., colon or intestinal tract), breast, lung, prostate, liver, spleen, pancreas, uterus, vagina, and other skin, mucous membrane, or serosal membrane.
[0048] The sample may be a cancer tissue sample, for example, from a tumor of the breast or prostate, in particular a human cancer tissue sample. In other embodiments, the sample is not obtained from cancer tissue (e.g., tissue without a substantial number of tumor cells). For example, the sample may be from an area of the skin (e.g., healthy skin) that is separated from nearby or adjacent cancer tissue. Thus, in some embodiments, the γδ T cells are not obtained from human cancer tissue.
[0049] In one embodiment, the sample has been obtained from a human.In an alternative embodiment, the sample has been obtained from a non-human animal subject.
[0050] Methods for obtaining such tissues are known in the art. Examples of such methods include scalpel removal or punch biopsy, and may vary in size depending on the method. In some embodiments, non-hematopoietic tissue samples are obtained by punch biopsy.
[0051] The methods described herein are performed outside the human or animal body, i.e., they are in vitro and / or ex vivo. Thus, in one embodiment, the methods described herein are in vitro methods. In another embodiment, the methods described herein are ex vivo methods.
[0052] As used herein, references to "expanded," "expanded populations," or "expanded γδ T cells" include cell populations that are larger or contain a greater number of cells than a non-expanded population. Such populations may be large, small, or mixed populations in which a portion or a particular cell type within a population is expanded. It should be understood that the term "expansion step" refers to the process of producing an expanded or expanded population. Thus, an expanded or expanded population may be larger in number or contain a greater number of cells than a population that has not yet undergone an expansion step or prior to any expansion step. It will also be understood that any number shown herein to indicate expansion (e.g., fold increase or fold expansion) illustrates an increase in the number or size of a cell population or the number of cells and indicates the amount of expansion.
[0053] In a preferred embodiment, the γδ T cells expanded by a method as defined herein comprise a population of Vδ1 T cells.
[0054] In other embodiments, the composition rich in γδT cells comprises NK cells. As described herein, step (i) comprises depleting αβT cells, i.e., preparing a composition rich in γδT cells by depleting αβT cells. In another embodiment, preparing a composition rich in γδT cells according to step (i) comprises depleting αβT cells from a mixed cell population obtained from a starting sample (such as a hematopoietic sample as described herein). The presence of NK cells in the composition may be advantageous because these cells are also effective cytotoxic cells.
[0055] NK cells (also known as large granular lymphocytes (LGL)) are cytotoxic lymphocytes of the innate immune system. They provide rapid responses to, for example, virus-infected cells and tumor cells, regardless of MHC expression on the surface of the target cells. Therefore, similar to γδ T cells, NK cell recognition of target cells is not MHC-restricted and they are not allogeneic HLA-reactive, which means that NK cell-based therapies do not require HLA matching of the patient.
[0056] In some embodiments, step (i) (ie, preparing a composition enriched for γδ T cells) additionally or alternatively comprises positively selecting for γδ+ T cells from a sample obtained from a subject comprising γδ T cells.
[0057] In one embodiment, the method comprises freezing the expanded γδT cells. Such frozen expanded γδT cells may then be thawed for downstream processing (such as further culture and expansion steps) and / or uses (such as therapeutic uses). Freezing allows for easy transportation and long-term storage of expanded γδT cells and is well known in the art. Therefore, it is advantageous to provide a method for cells that show good viability and activity after freezing and thawing, rather than all expansion methods producing such cells.
[0058] In one embodiment, the composition of γδ T cells is derived from a single donor. In an alternative embodiment, the composition is derived from multiple donors, ie the composition is a 'pooled' composition.
[0059] In one embodiment, the single or multiple donors may include a subject to be treated with a cell population or composition of the invention. Alternatively, the single or multiple donors do not include a subject to be treated with a cell population or composition of the invention.
[0060] Culture conditions
[0061] The method of the present invention cultivates γδT cells in the presence of a TCR agonist, particularly an anti-CD3 antibody or fragment thereof. The antibody can specifically bind to CD3. Preferred antibody clones include anti-CD3 antibodies, such as OKT-3 and UCHT-1 clones. In some aspects, fibronectin is used in combination with OKT-3.
[0062] The term "antibody" includes any antibody protein construct comprising at least one antibody variable domain containing at least one antigen binding site (ABS). Antibodies include, but are not limited to, immunoglobulins of IgA type, IgG type, IgE type, IgD type, IgM type (and its subtype). The overall structure of an immunoglobulin G (IgG) antibody assembled by two identical heavy (H) chains and two identical light (L) chain polypeptides is well defined and highly conserved in mammals (Padlan (1994) Mol. Immunol. 31: 169-217).
[0063] As used herein, a fragment of an antibody (also referred to as an "antibody fragment", "immunoglobulin fragment", "antigen binding fragment" or "antigen binding polypeptide") refers to a portion of an antibody (or a construct containing such a portion) that specifically binds to a target CD3 protein, which is part of a T cell receptor (TCR) complex (e.g., a molecule in which one or more immunoglobulin chains are not full-length but specifically binds to a target). Examples of binding fragments encompassed within the term antibody fragment include:
[0064] (i) Fab fragment (monovalent fragment consisting of VL, VH, CL and CH1 domains);
[0065] (ii) F(ab')2 fragment (a bivalent fragment consisting of two Fab fragments linked by a disulfide bridge at the hinge region);
[0066] (iii) Fd fragment (consisting of VH and CH1 domains);
[0067] (iv) Fv fragment (consisting of the VL and VH domains of a single arm of an antibody);
[0068] (v) single-chain variable fragment scFv (composed of the VL and VH domains linked using recombinant methods via a synthetic linker that enables the VL and VH domains to become a single protein chain, wherein the VL and VH regions pair to form a monovalent molecule);
[0069] (vi) VH (immunoglobulin chain variable domain consisting of the VH domain);
[0070] (vii) VL (immunoglobulin chain variable domain consisting of the VL domain);
[0071] (viii) domain antibodies (dAbs, consisting of VH or VL domains);
[0072] (ix) minibodies (composed of a pair of scFv fragments linked via a CH3 domain); and
[0073] (x) Diabodies (composed of non-covalent dimers of scFv fragments consisting of the VH domain of one antibody connected to the VL domain of another antibody via a small peptide linker).
[0074] "Specificity" refers to the number of different types of antigens or antigenic determinants that a particular antibody or its fragment can bind to. The specificity of an antibody is the ability of an antibody to recognize a particular antigen as a unique molecular entity and to distinguish it from another. An antibody that "specifically binds" to an antigen or epitope is a term fully understood in the art. If a molecule reacts with a specific targeted antigen or epitope more frequently, more quickly, with a greater duration and / or with a greater affinity than it reacts with an alternative target, it is considered to exhibit "specific binding". If an antibody binds to a target antigen or epitope with greater affinity, avidity, more easily and / or with a greater duration than it binds to other substances, it "specifically binds" to the target antigen or epitope. If the binding of an antibody (or its fragment) to a target is statistically significant compared to an unrelated binding agent, it can be considered to specifically bind to the target.
[0075] In one embodiment, the anti-CD3 antibody or fragment thereof is OKT3. This antibody is also known as Muromonab-CD3, which is a murine monoclonal antibody that targets an epitope located on the CD3 epsilon chain.
[0076] In one embodiment, the anti-CD3 antibody or fragment thereof is in a soluble or fixed form. For example, the antibody or fragment thereof can be applied to the composition in a soluble form. Alternatively, the antibody or fragment thereof can be applied to the composition when the antibody or fragment thereof is bound or covalently bonded to a surface (such as a bead or plate, i.e., in a fixed form). In one embodiment, the antibody is fixed to a surface (such as an Fc-coated well). Alternatively, the antibody or fragment thereof is bound to the surface of a cell (e.g., fixed to the surface of an antigen presenting cell (APC)). In another embodiment, when the composition is contacted with the antibody, the antibody is not fixed to the surface.
[0077] It should be understood that the culture of the composition of γδT cells is carried out for a certain duration, and the duration effectively produces an amplified population of γδT cells. In one embodiment, the duration of the amplified population of γδT cells is effectively produced for at least 7 days. Therefore, in one embodiment, the composition of γδT cells is cultured for at least 7 days. In another embodiment, the composition is cultured for 7 to 21 days, such as 9 to 15 days. In another embodiment, the composition is cultured for about 10, 11, 12, 13 or 14 days. In some aspects, the composition is cultured for at least about 7 days. In some aspects, the composition is cultured for at least about 8 days. In some aspects, the composition is cultured for at least about 9 days. In some aspects, the composition is cultured for at least about 10 days. In some aspects, the composition is cultured for at least about 11 days. In some aspects, the composition is cultured for at least about 12 days. In some aspects, the composition is cultured for at least about 13 days. In some aspects, the composition is cultured for at least about 14 days.
[0078] In other embodiments, the composition is cultured for at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, at least 14 days or at least 21 days (e.g., about 14 days or about 21 days) to produce an amplified population of γδT cells. In one embodiment, the composition is cultured for about 10, 11, 12, 13 or 14 days to produce an amplified population of γδT cells. In some aspects, the composition is cultured for at least about 5 days to produce an amplified population of γδT cells. In some aspects, the composition is cultured for at least about 6 days to produce an amplified population of γδT cells. In some aspects, the composition is cultured for at least about 7 days to produce an amplified population of γδT cells. In some aspects, the composition is cultured for at least about 8 days to produce an amplified population of γδT cells. In some aspects, the composition is cultured for at least about 9 days to produce an amplified population of γδT cells. In some aspects, the composition is cultured for at least about 10 days to produce an amplified population of γδT cells. In some aspects, the composition is cultured for at least about 11 days to produce an expanded population of γδT cells. In some aspects, the composition is cultured for at least about 12 days to produce an expanded population of γδT cells. In some aspects, the composition is cultured for at least about 13 days to produce an expanded population of γδT cells. In some aspects, the composition is cultured for at least about 14 days to produce an expanded population of γδT cells. In some aspects, the composition is cultured for at least about 15 days to produce an expanded population of γδT cells. In some aspects, the composition is cultured for at least about 16 days to produce an expanded population of γδT cells. In some aspects, the composition is cultured for at least about 17 days to produce an expanded population of γδT cells. In some aspects, the composition is cultured for at least about 18 days to produce an expanded population of γδT cells. In some aspects, the composition is cultured for at least about 19 days to produce an expanded population of γδT cells. In some aspects, the composition is cultured for at least about 20 days to produce an expanded population of γδT cells. In some aspects, the composition is cultured for at least about 21 days to produce an expanded population of γδT cells.
[0079] In certain embodiments of the present invention, the sample is cultured in a medium that is substantially free of serum (e.g., a medium that is free of serum or a medium containing a serum substitute (SR)). Therefore, in one embodiment, the sample is cultured in a medium that is free of serum. Such a medium that is free of serum may also include a serum replacement medium, wherein serum replacement is a component determined based on chemical composition to avoid the use of human or animal-derived serum. In an alternative embodiment, the sample is cultured in a medium containing serum (e.g., human AB serum or fetal bovine serum (FBS)). In one embodiment, the sample is cultured in a medium containing a serum substitute. In one embodiment, the sample is cultured in a medium that does not contain an animal-derived product. It should be understood that the embodiments of the present invention wherein the sample is cultured in a medium that does not contain serum have the advantages of avoiding filtration, precipitation, contamination, and supplying serum. In addition, animal-derived products are disadvantageous in the clinical-grade manufacture of human therapeutic agents.
[0080] In one embodiment, the method as defined herein is performed in a vessel (e.g., an expansion vessel) comprising a gas permeable material. Such materials are permeable to gases such as oxygen, carbon dioxide, and / or nitrogen, thereby allowing gas exchange between the vessel contents and the surrounding atmosphere. It should be understood that "vessels" mentioned herein include culture dishes, culture plates, single-hole dishes, multi-hole dishes, multi-hole plates, flasks, multi-layer flasks, bottles (such as roller bottles), bioreactors, bags, tubes, etc. Such vessels are known in the art for methods involving amplification of non-adherent cells and other lymphocytes. However, vessels comprising gas permeable materials are also unexpectedly found to be effective in the separation and amplification of γδT cells that are generally considered to be adherent. It is found that the use of such vessels for cultivation greatly increases the yield of amplified γδT cells. Compared to fibroblasts and other stromal cells (e.g., epithelial cells), including adherent cell types, it is also found that such vessels preferentially support γδT cells and other lymphocytes. See, e.g., International Publication Nos. WO2020095058 and WO2020095059, each of which is incorporated herein by reference in its entirety. Thus, in one embodiment, a vessel comprising a gas permeable material as defined herein preferentially supports γδT cells and other lymphocytes (e.g., αβT cells and / or NK cells). In another embodiment, fibroblasts and / or other stromal cells (e.g., epithelial cells) are absent in the culture carried out in a vessel comprising a gas permeable material.
[0081] Such vessels comprising gas permeable materials may additionally comprise non-porous gas permeable materials. Therefore, in one embodiment, the gas permeable material is non-porous. In some embodiments, the gas permeable material is a film, such as silicone, fluoroethylene polypropylene, polyolefin or ethylene vinyl acetate copolymer. In addition, such vessels may only comprise a portion of gas permeable materials, gas permeable films or non-porous gas permeable materials. Therefore, according to another embodiment, the vessel comprises a top, a bottom and at least one side wall, wherein at least a portion of the vessel bottom comprises a gas permeable material in a substantially horizontal plane when the top is above the bottom. In one embodiment, the vessel comprises a top, a bottom and at least one side wall, wherein at least a portion of the bottom comprises a gas permeable material in a horizontal plane when the top is above the bottom. In another embodiment, the vessel comprises a top, a bottom and at least one side wall, wherein at least a portion of the bottom comprises a gas permeable material in a vertical plane when the top is above the bottom or in a horizontal plane when the top is not above the bottom. It should be understood that in such embodiments, only a portion of the bottom or the side wall may comprise a gas permeable material. Alternatively, the entire bottom or the entire sidewall may comprise a gas permeable material. In another embodiment, the top comprising a gas permeable material in the vessel may be sealed, for example, by using an O-ring. Such embodiments will be suitable for preventing the contents of the vessel from overflowing or reducing its evaporation. Therefore, in certain embodiments, the vessel comprises a liquid-tight container, and the liquid-tight container comprises a gas permeable material to allow gas exchange. In alternative embodiments, the top comprising a gas permeable material in the vessel is in a horizontal plane and above the bottom and is not sealed. Therefore, in certain embodiments, the top is configured to allow gas exchange at the top of the vessel. In other embodiments, the bottom of the gas permeable container is configured to allow gas exchange at the bottom of the vessel. In another embodiment, the vessel comprising a gas permeable material may be a liquid-tight container and also comprises an inlet and outlet port or a pipe. Therefore, in certain embodiments, the vessel comprising a gas permeable material comprises a top, a bottom, and optionally at least one sidewall, wherein at least a portion of the top and the bottom comprises a gas permeable material, and (if present) at least a portion of at least one sidewall comprises a gas permeable material. Exemplary vessels are described in WO2005035728 and US9255243, which are incorporated herein by reference. These vessels are also commercially available, such as those provided by Wilson Wolf Manufacturing. Cell culture devices such as G-REX 6-well plates, G-REX 24-well plates, and G-REX 10 vessels.
[0082] Suitably the population of γδ T cells is expanded to provide at least 5-fold, particularly at least 10-fold or at least 15-fold, especially at least 20-fold the number of γδ T cells. In some aspects, the fold change is related to the starting population of γδ T cells.
[0083] The composition is cultured in a medium comprising IL-15. As used herein, "IL-15" refers to natural or recombinant IL-15 or a variant thereof, which acts as an agonist of one or more IL-15 receptor (IL-15R) subunits (e.g., mutants, mutant proteins, analogs, subunits, receptor complexes, fragments, isoforms, and peptidomimetics thereof). Like IL-2, IL-15 is a known T cell growth factor that can support the proliferation of the IL-2-dependent cell line CTLL-2. Grabstein et al. (Grabstein et al. Science 1994.264.5161:965-969) first reported that IL-15 is a 114 amino acid mature protein. As used herein, the term "IL-15" means natural or recombinant IL-15 and its mutant proteins, analogs, subunits, or complexes thereof (e.g., receptor complexes, such as sushi peptides described in WO 2007 / 046006), and each of which can stimulate the proliferation of CTLL-2 cells. In the CTLL-2 proliferation assay, supernatants from cells transfected with an in-frame fusion of recombinantly expressed pro- and mature forms of IL-15 can induce proliferation of CTLL-2 cells.
[0084] Human IL-15 can be obtained according to the procedure described by Grabstein et al. or by conventional procedures such as polymerase chain reaction (PCR). A deposit of human IL-15 cDNA was made and assigned accession number 69245.
[0085] The amino acid sequence of human IL-15 (gene number 3600) was found in the GenBank under the accession number NP000576.1 GI: 10835153 (isoform 1) and NP_751915.1 GI: 26787986 (isoform 2). The amino acid sequence of mouse (Mus musculus) IL-15 (gene number 16168) was found in the GenBank under the accession number NP_001241676.1 GI: 363000984.
[0086] IL-15 may also refer to IL-15 derived from a variety of mammalian species, including, for example, humans, monkeys, cows, pigs, horses, and mice. As referred to herein, an IL-15 "mutant" or "variant" is a polypeptide substantially homologous to the sequence of a native mammalian IL-15, but having an amino acid sequence that is different from the native mammalian IL-15 polypeptide due to amino acid deletions, insertions, or substitutions. The variant may contain a conservative substitution sequence, meaning that a given amino acid residue is replaced by a residue with similar physiochemical characteristics. Examples of conservative substitutions include substitutions of one aliphatic residue for another aliphatic residue, such as substitutions of Ile, Val, Leu, or Ala for each other, or substitutions of one polar residue for another polar residue, such as substitutions between Lys and Arg; Glu and Asp; or Gln and Asn. Other such conservative substitutions are well known, such as substitutions of entire regions with similar hydrophobic characteristics. The present invention also encompasses naturally occurring IL-15 variants. Examples of such variants are proteins produced by alternative mRNA splicing events or by proteolytic cleavage of IL-15 protein, in which IL-15 binding properties are retained. Alternative splicing of mRNA can produce truncated but biologically active IL-15 proteins. Changes attributable to proteolysis include, for example, differences in the N-terminus or C-terminus produced by proteolytic removal of one or more terminal amino acids (usually 1-10 amino acids) from the IL-15 protein after expression in different types of host cells. In some embodiments, the ends of the protein can be modified with, for example, chemical groups (such as polyethylene glycol) to change its physical properties (Yang et al. Cancer 1995.76:687-694). In some embodiments, the ends or interiors of the protein can be modified with other amino acids (Clark-Lewis et al. PNAS 1993.90:3574-3577).
[0087] In some embodiments, the methods defined herein typically are performed at a concentration of at least 0.1 ng / mL (such as at least 10 ng / mL, for example 0.1 ng / mL to 10,000 ng / mL, 1.0 ng / mL to 1,000 ng / mL, 5 ng / mL to 800 ng / mL, 10 ng / mL to 750 ng / mL, 20 ng / mL to 500 ng / mL, 50 ng / mL to 400 ng / mL or 100 ng / mL to 250 ng / mL, for example 0.1 ng / mL to 1.0 ng / mL, 1.0 ng / mL to 2 In some embodiments, the concentration of IL-15 is about 100 ng / mL. In some embodiments defined herein, IL-15 is included at a concentration of 5 ng / mL-300 ng / mL (e.g., 5 ng / mL-150 ng / mL), (e.g., 10 ng / mL-150 ng / mL), (e.g., 10 ng / mL-100 ng / mL). In some aspects, IL-15 is included at a concentration of about 5 ng / mL-250 ng / mL, about 5 ng / mL-200 ng / mL, about 5 ng / mL-150 ng / mL, about 10 ng / mL-250 ng / mL, about 10 ng / mL-200 ng / mL, about 10 ng / mL-150 ng / mL, about 20 ng / mL-250 ng / mL, about 20 ng / mL-200 ng / mL, about 20 ng / mL-150 ng / mL, about 30 ng / mL-250 ng / mL, about 30 ng / mL-20 0 ng / mL, about 30 ng / mL-150 ng / mL, about 40 ng / mL-250 ng / mL, about 40 ng / mL-200 ng / mL, about 40 ng / mL-150 ng / mL, about 50 ng / mL-250 ng / mL, about 50 ng / mL-200 ng / mL, about 50 ng / mL-150 ng / mL, about 10 ng / mL-125 ng / mL, about 10 ng / mL-100 ng / mL, or about 20 ng / mL-100 ng / mL includes IL-15.In some aspects, IL-15 is included at a concentration of about 5ng / mL to about 150ng / mL. In some aspects, IL-15 is included at a concentration of about 5ng / mL to about 125ng / mL. In some aspects, IL-15 is included at a concentration of about 5ng / mL to about 100ng / mL. In some aspects, IL-15 is included at a concentration of about 10ng / mL to about 150ng / mL. In some aspects, IL-15 is included at a concentration of about 10ng / mL to about 125ng / mL. In some aspects, IL-15 is included at a concentration of about 10ng / mL to about 100ng / mL. In some aspects, IL-15 is included at a concentration of about 15ng / mL to about 150ng / mL. In some aspects, IL-15 is included at a concentration of about 5-300 (e.g., wherein the range is 10-150). In some aspects, IL-15 is included at a concentration of about 15ng / mL to about 125ng / mL. In some aspects, IL-15 is included at a concentration of about 15ng / mL to about 100ng / mL. In some aspects, IL-15 is included at a concentration of about 20ng / mL to about 150ng / mL. In some aspects, IL-15 is included at a concentration of about 20ng / mL to about 125ng / mL. In some aspects, IL-15 is included at a concentration of about 20ng / mL to about 100ng / mL. In some aspects, IL-15 is included at a concentration of about 25ng / mL to about 150ng / mL. In some aspects, IL-15 is included at a concentration of about 25ng / mL to about 125ng / mL. In some aspects, IL-15 is included at a concentration of about 25ng / mL to about 100ng / mL.
[0088] In some aspects, IL-15 is included at a concentration of about 5 ng / mL. In some aspects, IL-15 is included at a concentration of about 10 ng / mL. In some aspects, IL-15 is included at a concentration of about 15 ng / mL. In some aspects, IL-15 is included at a concentration of about 20 ng / mL. In some aspects, IL-15 is included at a concentration of about 21 ng / mL. In some aspects, IL-15 is included at a concentration of about 25 ng / mL. In some aspects, IL-15 is included at a concentration of about 30 ng / mL. In some aspects, IL-15 is included at a concentration of about 35 ng / mL. In some aspects, IL-15 is included at a concentration of about 40 ng / mL. In some aspects, IL-15 is included at a concentration of about 45 ng / mL. In some aspects, IL-15 is included at a concentration of about 50 ng / mL. In some aspects, IL-15 is included at a concentration of about 60 ng / mL. In some aspects, IL-15 is included at a concentration of about 70 ng / mL. In some aspects, IL-15 is included at a concentration of about 80 ng / mL. In some aspects, IL-15 is included at a concentration of about 90 ng / mL. In some aspects, IL-15 is included at a concentration of about 100 ng / mL. In some aspects, IL-15 is included at a concentration of about 110 ng / mL. In some aspects, IL-15 is included at a concentration of about 120 ng / mL. In some aspects, IL-15 is included at a concentration of about 130 ng / mL. In some aspects, IL-15 is included at a concentration of about 140 ng / mL. In some aspects, IL-15 is included at a concentration of about 150 ng / mL.
[0089] In one embodiment, the composition is cultured in a medium consisting essentially of an anti-CD3 antibody or fragment thereof and IL-15. "Essentially consisting of" when used to define compositions and methods will mean excluding other elements that are important to the composition for the intended purpose. Thus, a composition consisting essentially of elements as defined herein will not exclude standard culture medium components, such as culture medium (CTS OpTmizer, Thermo Fisher), plasma, serum, and essential amino acids, such as L-glutamine (e.g., Glutamax).
[0090] Alternatively, the method (particularly such as in step (ii)) may comprise culturing the composition enriched for γδ T cells in the presence of one or more additional cytokines selected from the group consisting of IL-2, IL-21 and IL-1β.
[0091] In some aspects, cells are seeded in a culture medium comprising anti-CD3 antibodies and IL-15, wherein the culture medium does not include another exogenous cytokine. In some aspects, cells are seeded in a culture medium comprising anti-CD3 antibodies and IL-15, wherein the culture medium does not include IL-4. In some aspects, cells are seeded in a culture medium comprising anti-CD3 antibodies and IL-15, wherein the culture medium does not include IL-1β. In some aspects, cells are seeded in a culture medium comprising anti-CD3 antibodies and IL-15, wherein the culture medium does not include IL-21. In some aspects, cells are seeded in a culture medium comprising anti-CD3 antibodies and IL-15, wherein the culture medium does not include IFNγ. In some aspects, cells are seeded in a culture medium comprising anti-CD3 antibodies and IL-15, wherein the culture medium does not include IL-2. In some aspects, cells are seeded in a culture medium comprising anti-CD3 antibodies and IL-15, wherein the culture medium does not include IL-9.
[0092] In some aspects, hematopoietic system-derived γδ cells are inoculated in a culture medium comprising anti-CD3 antibodies and IL-15, wherein the culture medium does not contain another exogenous cytokine. In some aspects, hematopoietic system-derived γδ cells are inoculated in a culture medium comprising anti-CD3 antibodies and IL-15, wherein the culture medium does not contain IL-4. In some aspects, hematopoietic system-derived γδ cells are inoculated in a culture medium comprising anti-CD3 antibodies and IL-15, wherein the culture medium does not contain IL-1β. In some aspects, hematopoietic system-derived γδ cells are inoculated in a culture medium comprising anti-CD3 antibodies and IL-15, wherein the culture medium does not contain IL-21. In some aspects, hematopoietic system-derived γδ cells are inoculated in a culture medium comprising anti-CD3 antibodies and IL-15, wherein the culture medium does not contain IFNγ. In some aspects, hematopoietic system-derived γδ cells are inoculated in a culture medium comprising anti-CD3 antibodies and IL-15, wherein the culture medium does not contain IL-2. In some aspects, hematopoietic-derived γδ cells are plated in a medium comprising an anti-CD3 antibody and IL-15, wherein the medium does not comprise IL-9.
[0093] In some aspects, after inoculation, additional IL-15 is added to the cell culture medium. In some aspects, at least one day, at least two days, at least three days, at least four days, at least five days, at least 6 days or at least 7 days, additional IL-15 (for example, wherein IL-15 is added with the amount of 5-150ng / ml) (for example, 15-115ng / ml) is added. In some aspects, after inoculation, additional IL-15 (for example, wherein IL-15 is added with the amount of 5-150ng / ml) (for example, 15-115ng / ml) is added in the 1st day culture medium. In some aspects, after inoculation, additional IL-15 (for example, wherein IL-15 is added with the amount of 5-150ng / ml) (for example, 15-115ng / ml) is added in the 2nd day culture medium. In some aspects, after inoculation, additional IL-15 (for example, wherein IL-15 is added with the amount of 5-150ng / ml) (for example, 15-115ng / ml) is added in the 3rd day culture medium. In some aspects, additional IL-15 (e.g., IL-15 is added in an amount of 5-150ng / ml) (e.g., 15-115ng / ml) is added to the culture medium on the 4th day after inoculation. In some aspects, additional IL-15 (e.g., IL-15 is added in an amount of 5-150ng / ml) (e.g., 15-115ng / ml) is added to the culture medium on the 5th day after inoculation. In some aspects, additional IL-15 (e.g., IL-15 is added in an amount of 5-150ng / ml) (e.g., 15-115ng / ml) is added to the culture medium on the 6th day after inoculation. In some aspects, additional IL-15 (e.g., IL-15 is added in an amount of 5-150ng / ml) (e.g., 15-115ng / ml) is added to the culture medium on the 7th day after inoculation. In some aspects, additional IL-15 (e.g., IL-15 is added in an amount of 5-150ng / ml) (e.g., 15-115ng / ml) is added to the culture medium on the 8th day after inoculation. In some aspects, additional IL-15 (e.g., wherein IL-15 is added in an amount of 5-150ng / ml) (e.g., 15-115ng / ml) is added to the culture medium at day 9 after inoculation. In some aspects, additional IL-15 (e.g., wherein IL-15 is added in an amount of 5-150ng / ml) (e.g., 15-115ng / ml) is added to the culture medium at day 10 after inoculation. In some aspects, additional IL-15 (e.g., wherein IL-15 is added in an amount of 5-150ng / ml) (e.g., 15-115ng / ml) is added to the culture medium at day 11 after inoculation. In some aspects, additional IL-15 (e.g., wherein IL-15 is added in an amount of 5-150ng / ml) (e.g., 15-115ng / ml) is added to the culture medium at day 12 after inoculation.In some aspects, additional IL-15 (e.g., wherein IL-15 is added in an amount of 5-150 ng / ml) (e.g., 15-115 ng / ml) is added to the culture medium on day 13 after inoculation. In some aspects, additional IL-15 (e.g., wherein IL-15 is added in an amount of 5-150 ng / ml) (e.g., 15-115 ng / ml) is added on day 14 after inoculation.
[0094] In some aspects, additional IL-15 (e.g., wherein IL-15 is added in an amount of 5-150 ng / ml) is added on the 4th, 5th, 6th, and 7th days after inoculation (e.g., 15-115 ng / ml). In some aspects, additional IL-15 (e.g., wherein IL-15 is added in an amount of 5-150 ng / ml) is added on the 10th, 11th, and 12th days after inoculation (e.g., 15-115 ng / ml). In some aspects, additional IL-15 (e.g., wherein IL-15 is added in an amount of 5-150 ng / ml) is added on the 16th, 17th, and 18th days after inoculation (e.g., 15-115 ng / ml).
[0095] In some aspects, no other cytokines are added with the additional IL- 15. Thus, in some aspects, the cells are cultured in the absence of exogenously added IL-4, IL-1β, IL-21, IFNγ, or any combination thereof for the culture duration.
[0096] In some aspects, cells are cultured for at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, at least about 14 days, at least about 15 days, at least about 16 days, at least about 17 days, at least about 18 days, at least about 19 days, at least about 20 days, or at least about 21 days according to the methods disclosed herein. In some aspects, cells are cultured for at least about 7 days according to the methods disclosed herein. In some aspects, cells are cultured for at least about 8 days according to the methods disclosed herein. In some aspects, cells are cultured for at least about 9 days according to the methods disclosed herein. In some aspects, cells are cultured for at least about 10 days according to the methods disclosed herein. In some aspects, cells are cultured for at least about 11 days according to the methods disclosed herein. In some aspects, cells are cultured for at least about 12 days according to the methods disclosed herein. In some aspects, cells are cultured for at least about 13 days according to the methods disclosed herein. In some aspects, cells are cultured for at least about 14 days according to the methods disclosed herein. In some aspects, cells are cultured for at least about 15 days according to the methods disclosed herein. In some aspects, cells are cultured for at least about 16 days according to the methods disclosed herein. In some aspects, cells are cultured for at least about 17 days according to the methods disclosed herein. In some aspects, cells are cultured for at least about 18 days according to the methods disclosed herein. In some aspects, cells are cultured for at least about 19 days according to the methods disclosed herein. In some aspects, cells are cultured for at least about 20 days according to the methods disclosed herein. In some aspects, cells are cultured for at least about 21 days according to the methods disclosed herein.
[0097] In some aspects, cells are contacted with IL-21. As used herein, "IL-21" refers to natural or recombinant IL-21 or its variants, which act as agonists of one or more IL-21 receptors (IL-21R) subunits (e.g., mutants, mutant proteins, analogs, subunits, receptor complexes, fragments, isotypes, and peptidomimetics). Such agents can support natural killer (NK) and cytotoxicity (CD8 +)T cell proliferation.Mature human IL-21 exists in the form of 133 amino acid sequences (signal peptide is smaller, is composed of other 22 N-terminal amino acids).IL-21 mutant proteins are polypeptides that have been specifically substituted for interleukin-21 protein and retained the ability of combining IL-21R α simultaneously, such as those described in US 9,388,241.IL-21 mutant proteins can be characterized by amino acid insertion, deletion, replacement and modification in other residues of natural IL-21 polypeptide chain or one or more sites of other residues.According to the disclosure, any such insertion, deletion, replacement and modification all produce the IL-21 mutant proteins that retain the IL-21R binding activity.Exemplary mutant proteins can include 1,2,3,4,5,6,7,8,9,10 or more amino acid replacements.
[0098] The nucleic acid encoding human IL-21 can be obtained by conventional procedures such as polymerase chain reaction (PCR). The amino acid sequence of human IL-21 (gene number 59067) was found in the gene bank according to the accession number NC_000004.12. The mouse (Mus musculus) IL-21 amino acid sequence (gene number 60505) was found in the gene bank according to the accession number NC_000069.6.
[0099] IL-21 may also refer to IL-21 derived from a variety of mammalian species, including, for example, humans, monkeys, cattle, pigs, horses, and mice. Variants may include conservative substitution sequences, meaning that a given amino acid residue is replaced by a residue with similar physiochemical characteristics. Examples of conservative substitutions include substitutions of one aliphatic residue to another aliphatic residue, such as substitutions of Ile, Val, Leu, or Ala to each other, or substitutions of one polar residue to another polar residue, such as Lys and Arg; Glu and Asp; or substitutions between Gln and Asn. Other such conservative substitutions are well known, such as substitutions of entire regions with similar hydrophobic characteristics. The present invention also encompasses naturally occurring IL-21 variants. Examples of such variants are proteins produced by alternative mRNA splicing events or by proteolytic cleavage of IL-21 proteins, in which IL-21 binding properties are retained. Variable splicing of mRNA can produce truncated but biologically active IL-21 proteins. Changes attributable to proteolysis include, for example, differences in the N-terminus or C-terminus resulting from proteolytic removal of one or more terminal amino acids (usually 1-10 amino acids) from the IL-21 protein after expression in different types of host cells. In some embodiments, the ends of the protein may be modified with, for example, chemical groups (such as polyethylene glycol) to alter its physical properties (Yang et al. Cancer 1995. 76: 687-694). In some embodiments, the ends or interior of the protein may be modified with other amino acids (Clark-Lewis et al. PNAS 1993. 90: 3574-3577).
[0100] In other embodiments, the methods defined herein typically include IL-21 at a concentration of at least 0.1 ng / mL (such as at least 1.0 ng / mL, for example 0.1 ng / mL to 1,000 ng / mL, 1.0 ng / mL to 100 ng / mL, 1.0 ng / mL to 50 ng / mL, 2 ng / mL to 50 ng / mL, 3 ng / mL to 10 ng / mL, 4 ng / mL to 8 ng / mL, 5 ng / mL to 10 ng / mL, 6 ng / mL to 8 ng / mL, for example 0.1 ng / mL to 10 ng / mL, 1.0 ng / mL to 5 ng / mL, 1.0 ng / mL to 10 ng / mL, 1.0 ng / mL to 20 ng / mL). In other embodiments, the methods defined herein typically include IL-21 at a concentration of less than 100 ng / mL (such as less than 50 ng / mL). In some aspects, the concentration of IL-21 is 3 ng / mL to 40 ng / mL, 4 ng / mL to 20 ng / mL, 5 ng / mL to 15 ng / mL, or 6 ng / mL to 10 ng / mL. In some aspects, the cells are not contacted with IL-21.
[0101] In some aspects, the cell is contacted with IL-2. As used herein, "IL-2" refers to natural or recombinant IL-2 or a variant thereof that acts as an agonist of one or more IL-2 receptor (IL-2R) subunits (e.g., mutants, mutant proteins, analogs, subunits, receptor complexes, fragments, isoforms, and peptidomimetics thereof). Such agents can support the IL-2-dependent cell line CTLL-2 (33; American Type Culture Collection TIB 214). As described in Fujita et al. Cell 1986.46.3:401-407, mature human IL-2 exists in the form of a 133 amino acid sequence (the signal peptide is smaller, consisting of an additional 20 N-terminal amino acids). IL-2 mutant proteins are polypeptides in which interleukin-2 proteins have been specifically substituted while retaining the ability to bind to IL-2Rβ, such as those described in US2014 / 0046026. IL-2 mutant proteins can be characterized by amino acid insertions, deletions, substitutions, and modifications at one or more sites in other residues or other residues of the native IL-2 polypeptide chain. According to the present disclosure, any such insertions, deletions, substitutions, and modifications produce IL-2 mutant proteins that retain IL-2Rβ binding activity. Exemplary mutant proteins may include substitutions of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acids.
[0102] Nucleic acids encoding human IL-2 can be obtained by conventional procedures such as polymerase chain reaction (PCR). The amino acid sequence of human IL-2 (gene number 3558) was found in the gene bank according to the accession number NP_000577.2GI:28178861. The amino acid sequence of mouse (Mus musculus) IL-2 (gene number 16183) was found in the gene bank according to the accession number NP_032392.1GI:7110653.
[0103] IL-2 may also refer to IL-2 derived from a variety of mammalian species, including, for example, humans, monkeys, cows, pigs, horses, and mice. Variants may contain conservative substitution sequences, meaning that a given amino acid residue is replaced by a residue with similar physiochemical characteristics. Examples of conservative substitutions include substitutions of one aliphatic residue to another aliphatic residue, such as substitutions of Ile, Val, Leu, or Ala to each other, or substitutions of one polar residue to another polar residue, such as Lys and Arg; Glu and Asp; or substitutions between Gln and Asn. Other such conservative substitutions are well known, such as substitutions of entire regions with similar hydrophobic characteristics. The present invention also encompasses naturally occurring IL-2 variants. Examples of such variants are proteins produced by alternative mRNA splicing events or by proteolytic cleavage of IL-2 proteins, in which IL-2 binding properties are retained. Variable splicing of mRNA can produce truncated but biologically active IL-2 proteins. Changes attributable to proteolysis include, for example, differences in the N-terminus or C-terminus resulting from proteolytic removal of one or more terminal amino acids (usually 1-10 amino acids) from the IL-2 protein after expression in different types of host cells. In some embodiments, the ends or interior of the protein may be modified with, for example, chemical groups (such as polyethylene glycol) to alter its physical properties (Yang et al. Cancer 1995. 76: 687-694). In some embodiments, the ends or interior of the protein may be modified with other amino acids (Clark-Lewis et al. PNAS 1993. 90: 3574-3577).
[0104] In certain embodiments, the methods defined herein are typically administered at a concentration of at least 10 IU / mL (such as at least 100 IU / mL, for example 10 IU / mL to 1,000 IU / mL, 20 IU / mL to 800 IU / mL, 25 IU / mL to 750 IU / mL, 30 IU / mL to 700 IU / mL, 40 IU / mL to 600 IU / mL, 50 IU / mL to 500 IU / mL, 75 IU / mL to 250 IU / mL or 100 IU / mL to 200 IU / mL). , for example, 10IU / mL to 20IU / mL, 20IU / mL to 30IU / mL, 30IU / mL to 40IU / mL, 40IU / mL to 50IU / mL, 50IU / mL to 75IU / mL, 75IU / mL to 100IU / mL, 100IU / mL to 150IU / mL, 150IU / mL to 200IU / mL, 200IU / mL to 500IU / mL or 500IU / mL to 1,000IU / mL) concentration includes IL-2. In certain embodiments, the method defined herein typically includes IL-2 at a concentration of less than 1,000IU / mL (such as less than 500IU / mL). In some embodiments, the concentration of IL-2 is about 100IU / mL. In some aspects, cells are not in contact with IL-2.
[0105] In some aspects, the cell is contacted with IL-1β. As used herein, "IL-1β" refers to natural or recombinant IL-1β or a variant thereof, which acts as an agonist of one or more IL-1 receptor (IL-1R) subunits (e.g., mutants, mutant proteins, analogs, subunits, receptor complexes, fragments, isoforms, and peptidomimetics thereof). IL-1 is a proinflammatory cytokine that plays a major role in a wide range of diseases, including inflammatory diseases. It consists of two molecular species: IL-1α and IL-1β, which have only limited sequence identity but exert similar biological activities by binding to IL-1 receptors (type I and type II). As described in Andrei et al. (2004) PNAS101 (26): 9745-9750, after cleavage of 116 amino acids from the N-terminus of the precursor polypeptide by CASP1, mature human IL-1β exists in the form of a 153 amino acid sequence. IL-1β mutants are polypeptides in which specific substitutions have been made to the IL-1β protein while retaining the ability to bind to IL-1R. IL-1β mutants can be characterized by amino acid insertions, deletions, substitutions, and modifications at one or more sites in other residues of the native IL-1β polypeptide chain or at other residues. According to the present disclosure, any such insertions, deletions, substitutions, and modifications produce IL-1β mutants that retain IL-1R binding activity. Exemplary mutant proteins may include substitutions of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acids.
[0106] Nucleic acids encoding human IL-1β can be obtained by conventional procedures such as polymerase chain reaction (PCR). The amino acid sequence of human IL-1β (gene number 3553) is found in the gene bank according to the accession number NP_000567 or in UniProt according to the accession number P01584. The mouse (Mus musculus) IL-1β amino acid sequence (gene number 16176) is found in the gene bank according to the accession number NP_032387 or in UniProt according to the accession number P10749.
[0107] IL-1β may also refer to IL-1β derived from a variety of mammalian species, including, for example, humans, monkeys, cows, pigs, horses, and mice. Variants may contain conservative substitution sequences, meaning that a given amino acid residue is replaced by a residue with similar physiochemical characteristics. Examples of conservative substitutions include substitutions of one aliphatic residue for another aliphatic residue, such as substitutions of Ile, Val, Leu, or Ala for each other, or substitutions of one polar residue for another polar residue, such as Lys and Arg; Glu and Asp; or substitutions between Gln and Asn. Other such conservative substitutions are well known, such as substitutions of entire regions with similar hydrophobic characteristics. The present invention also encompasses naturally occurring IL-1β variants. Examples of such variants are proteins produced by alternative mRNA splicing events or by proteolytic cleavage of IL-1β proteins, in which IL-1β binding properties are retained.
[0108] In certain embodiments, the method defined herein typically includes IL-1β at a concentration of at least 100IU / mL (such as at least 1,000IU / mL, for example 100IU / mL to 8,000IU / mL, 250IU / mL to 7,000IU / mL, 500IU / mL to 6,000IU / mL or 1,000IU / mL to 5,000IU / mL). In certain embodiments, the method defined herein typically includes IL-1β at a concentration of less than 8,000IU / mL (such as less than 5,000IU / mL). In some embodiments, the concentration of IL-1β is about 4,500IU / mL. In some aspects, cells are not in contact with IL-1β.
[0109] In contrast to methods previously described in the art for expanding γδ T cells, the current method cultures the γδ T cell-enriched composition in the absence of IL-4. Thus, the method of the present invention is performed in a culture medium that does not contain (and is not supplemented with) IL-4.
[0110] In some aspects, the cell is not in contact with IL-4. As used herein, "IL-4" refers to natural or recombinant IL-4 or a variant thereof, which acts as an agonist of one or more IL-4 receptor (IL-4R) subunits (e.g., mutants, mutant proteins, analogs, subunits, receptor complexes, fragments, isoforms, and peptidomimetics). Such agents can support the differentiation of naive helper T cells (Th0 cells) into Th2 cells. Mature human IL-4 exists in the form of a 129 amino acid sequence (the signal peptide is smaller, consisting of another 24 N-terminal amino acids). IL-4 mutant proteins are polypeptides in which interleukin-4 proteins have been specifically substituted while retaining the ability to bind to IL-4Rα, such as those described in U.S. Patent No. 6,313,272. IL-4 mutant proteins can be characterized by amino acid insertion, deletion, substitution, and modification at one or more sites in other residues of the natural IL-4 polypeptide chain or at other residues. According to the present disclosure, any such insertions, deletions, substitutions and modifications result in IL-4 mutant proteins that retain IL-2Rα binding activity. Exemplary mutant proteins may include substitutions of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more amino acids.
[0111] Nucleic acids encoding human IL-4 can be obtained by conventional procedures such as polymerase chain reaction (PCR). The amino acid sequence of human IL-4 (gene number 3565) was found in the gene bank according to the accession number NG_023252. The amino acid sequence of mouse (Mus musculus) IL-4 (gene number 16189) was found in the gene bank according to the accession number NC_000077.6.
[0112] IL-4 may also refer to IL-4 derived from a variety of mammalian species, including, for example, humans, monkeys, cows, pigs, horses, and mice. Variants may contain conservative substitution sequences, meaning that a given amino acid residue is replaced by a residue with similar physiochemical characteristics. Examples of conservative substitutions include substitutions of one aliphatic residue for another aliphatic residue, such as substitutions of Ile, Val, Leu, or Ala for each other, or substitutions of one polar residue for another polar residue, such as Lys and Arg; Glu and Asp; or substitutions between Gln and Asn. Other such conservative substitutions are well known, such as substitutions of entire regions with similar hydrophobic characteristics. The present invention also encompasses naturally occurring IL-4 variants. Examples of such variants are proteins produced by alternative mRNA splicing events or by proteolytic cleavage of IL-4 proteins, in which IL-4 binding properties are retained. Variable splicing of mRNA can produce truncated but biologically active IL-4 proteins. Variations attributable to proteolysis include, for example, differences in the N-terminus or C-terminus resulting from proteolytic removal of one or more terminal amino acids (usually 1-10 amino acids) from the IL-4 protein following expression in different types of host cells.
[0113] Composition and markers
[0114] In some embodiments, at least 80% (such as 85%, 90%, 95%, 97%, 98%, 99%, 99.5%) of the cells present in the cell population include NK cells and γδT cells (eg, Vδ1T cells). In some embodiments, at least 80% (such as 85%, 90%, 95%, 97%, 98%, 99%, 99.5%) of the cells present in the cell population obtained by the methods described herein include NK cells and γδT cells. In one embodiment, at least 85% of the cells present in the cell population include NK and γδT cells. In another embodiment, at least 90% of the cells present in the cell population include NK cells and γδT cells. In another embodiment, at least 95% of the cells present in the cell population include NK cells and γδT cells.
[0115] In some embodiments, at least 50% of the cells present in the composition are γδT cells. In some embodiments, the composition comprises at least about 50% of γδT cells, such as at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% of γδT cells. In another embodiment, the composition comprises at least about 60% of γδT cells, such as greater than about 70% of γδT cells. In other embodiments, at least 80% (such as at least 90%) of the cells present in the composition are γδT cells. In one embodiment, the composition comprises at least about 82% of γδT cells.
[0116] In some embodiments, the composition comprises at least about 30% of Vδ1T cells, such as at least about 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49% or 50% of Vδ1T cells. In another embodiment, the composition comprises at least about 40% of Vδ1T cells, such as at least about 50% of Vδ1T cells. In some embodiments, the composition comprises about 50% to 70% of Vδ1T cells. In one embodiment, the composition comprises about 60% of Vδ1T cells.
[0117] In some aspects, the composition comprises less than about 1% αβ T cells. In some aspects, the composition comprises less than about 1% αβ T cells, less than about 0.9% αβ T cells, less than about 0.8% αβ T cells, less than about 0.7% αβ T cells, less than about 0.6% αβ T cells, less than about 0.5% αβ T cells, less than about 0.4% αβ T cells, less than about 0.3% αβ T cells, less than about 0.2% αβ T cells, less than about 0.1% αβ T cells, less than about 0.09% αβ T cells, less than about 0.08% αβ T cells, less than about 0.07% αβ T cells, less than About 0.06% of αβT cells, less than about 0.05% of αβT cells, less than about 0.04% of αβT cells, less than about 0.05% of αβT cells, less than about 0.04% of αβT cells, less than about 0.03% of αβT cells, less than about 0.02% of αβT cells, less than about 0.01% of αβT cells, less than about 0.009% of αβT cells, less than about 0.008% of αβT cells, less than about 0.007% of αβT cells, less than about 0.006% of αβT cells, less than about 0.005% of αβT cells. In some aspects, the composition comprises less than about 0.9% of αβT cells. In some aspects, the composition comprises less than about 0.8% of αβT cells. In some aspects, the composition comprises less than about 0.7% of αβT cells. In some aspects, the composition comprises less than about 0.6% of αβT cells. In some aspects, the composition comprises less than about 0.5% of αβT cells. In some aspects, the composition comprises less than about 0.4% of αβT cells. In some aspects, the composition comprises less than about 0.3% of αβT cells. In some aspects, the composition comprises less than about 0.2% of αβT cells. In some aspects, the composition comprises less than about 0.1% of αβT cells. In some aspects, the composition comprises less than about 0.09% of αβT cells. In some aspects, the composition comprises less than about 0.08% of αβT cells. In some aspects, the composition comprises less than about 0.07% of αβT cells. In some aspects, the composition comprises less than about 0.06% of αβT cells. In some aspects, the composition comprises less than about 0.05% of αβT cells. In some aspects, the composition comprises less than about 0.04% of αβT cells. In some aspects, the composition comprises less than about 0.03% αβ T cells. In some aspects, the composition comprises less than about 0.02% αβ T cells. In some aspects, the composition comprises less than about 0.01% αβ T cells. In some aspects, the composition comprises a concentration of αβ T cells below the limit of detection.
[0118] In some aspects, at least about 50% of the cells isolated before the expansion methods disclosed herein are αβT cells, and less than about 1% of the cells in the composition after expansion according to the methods disclosed herein are αβT cells. In some aspects, at least about 45% of the cells isolated before the expansion methods disclosed herein are αβT cells, and less than about 1% of the cells in the composition after expansion according to the methods disclosed herein are αβT cells. In some aspects, at least about 40% of the cells isolated before the expansion methods disclosed herein are αβT cells, and less than about 1% of the cells in the composition after expansion according to the methods disclosed herein are αβT cells. In some aspects, at least about 35% of the cells isolated before the expansion methods disclosed herein are αβT cells, and less than about 1% of the cells in the composition after expansion according to the methods disclosed herein are αβT cells. In some aspects, at least about 30% of the cells isolated before the expansion methods disclosed herein are αβT cells, and less than about 1% of the cells in the composition after expansion according to the methods disclosed herein are αβT cells. In some aspects, at least about 25% of the cells isolated before the expansion methods disclosed herein are αβT cells, and less than about 1% of the cells in the composition after expansion according to the methods disclosed herein are αβT cells. In some aspects, at least about 20% of the cells isolated before the expansion methods disclosed herein are αβT cells, and less than about 1% of the cells in the composition after expansion according to the methods disclosed herein are αβT cells. In some aspects, at least about 15% of the cells isolated before the expansion methods disclosed herein are αβT cells, and less than about 1% of the cells in the composition after expansion according to the methods disclosed herein are αβT cells. In some aspects, at least about 10% of the cells isolated prior to the expansion methods disclosed herein are αβ T cells, and less than about 1% of the cells in the composition after expansion according to the methods disclosed herein are αβ T cells. In some aspects, at least about 5% of the cells isolated prior to the expansion methods disclosed herein are αβ T cells, and less than about 1% of the cells in the composition after expansion according to the methods disclosed herein are αβ T cells.
[0119] In one embodiment, at least 50% of the expanded γδT cells present in the cell population express CD56. In one embodiment, at least about 60% (such as at least 65%, 70%, 75% or 80%) of the expanded γδT cells present in the cell population express CD56. In another embodiment, at least 80% of the expanded γδT cells present in the cell population express CD56, for example after a period of about 14 days (such as 14 days) of culture.
[0120] CD56 is also called neural cell adhesion molecule (NCAM), which is an adhesion molecule of the immunoglobulin (Ig) superfamily associated with high cytotoxicity in NK cells, αβT cells, and γδT cells. It has been shown to be involved in cis- and trans-binding to itself, which promotes lymphocyte activation. It has also been shown to be the basis for the formation of immune synapses between lymphocytes, lymphocytes and antigen-presenting cells (APCs), and lymphocytes and target cells (Nussbaumer and Thurnher (2020) Cells 9(3):772). Cell phenotypes can also be defined by the cell surface density of CD56. Therefore, there are CD56 known in the art. 明 and CD56 暗 CD56 is a type of cell that has been identified. Increased expression and / or intensity of CD56 on γδ T cells has been shown to correlate with increased killing. CD56 surface expression can be determined using methods known in the art, such as by analyzing staining intensity via flow cytometry. 明 and CD56 暗 As understood in the art, for example, as described in VanAcker et al. (2017) Front. Immunol. 8:892. Such methods compare a sample population to a reference population with known CD56 expression levels, such as a cell population containing NK cells. NK cells have unique CD56 expression levels that can be identified as bright and dark, so by using this reference population to determine the gating strategy, the sample population can also be sorted to CD56 明 and CD56 暗 In the fraction.
[0121] In one embodiment, the cell colony comprises γδT cells expressing CD56, NKp30, CD57, GITR, TIGIT, CCR6, CCR2, CCR5 and / or CXCR6 (such as CD56, NKp30, CD57, GITR and / or TIGIT). In another embodiment, the cell colony comprises γδT cells expressing CD56, NKp30, CD57, GITR and TIGIT. In some aspects, the cell colony comprises γδT cells expressing NKp30. In some aspects, the cell colony comprises γδT cells expressing NKG2D. In some aspects, the cell colony comprises γδT cells expressing DNAM-1. In some aspects, the cell colony comprises γδT cells expressing CD57. In some aspects, the cell colony comprises γδT cells expressing GITR. In some aspects, the cell colony comprises γδT cells expressing TIGIT. In some aspects, the cell colony comprises γδT cells expressing CXCR3. In some aspects, the cell colony comprises γδT cells expressing CXCR4. In some aspects, the cell colony comprises γδT cells expressing CCR4. In some aspects, the cell colony comprises γδT cells expressing CCR6. In some aspects, the cell colony comprises γδT cells expressing CCR2. In some aspects, the cell colony comprises γδT cells expressing CCR5. In some aspects, the cell colony comprises γδT cells expressing CXCR6.
[0122] In some aspects, the cell colony comprises γδT cells that secrete IFNδ. In some aspects, the cell colony comprises γδT cells that secrete IFNδ at a higher level than cells amplified using standard techniques. In some aspects, the cell colony comprises γδT cells that secrete GM-CSF at a higher level than cells amplified using standard techniques. In some aspects, the cell colony comprises γδT cells that secrete GM-CSF at a higher level than cells amplified using standard techniques. In some aspects, the cell colony comprises γδT cells that secrete CXCL9. In some aspects, the cell colony comprises γδT cells that secrete CXCL9 at a higher level than cells amplified using standard techniques. In some aspects, the cell colony comprises γδT cells that secrete CXCL10. In some aspects, the cell colony comprises γδT cells that secrete CXCL10 at a higher level than cells amplified using standard techniques. In some aspects, the cell colony comprises γδT cells that secrete CCL3. In some aspects, the cell colony comprises γδT cells that secrete CCL3 at a higher level than cells amplified using standard techniques. In some aspects, the cell colony comprises γδT cells that secrete CCL4. In some aspects, the cell colony comprises γδT cells that secrete CCL4 at a higher level than cells amplified using standard techniques. In some aspects, the cell colony comprises γδT cells that secrete CCL7. In some aspects, the cell colony comprises γδT cells that secrete CCL7 at a higher level than cells amplified using standard techniques. In some aspects, the cell colony comprises γδT cells that secrete CCL20. In some aspects, the cell colony comprises γδT cells that secrete CCL20 at a higher level than cells amplified using standard techniques.
[0123] In some embodiments, the expansion method as provided herein produces an expansion cell population of γδT cells (particularly Vδ1T cells) with high specific marker expression relative to a reference population (e.g., an isolated population of γδT cells before the expansion step). Such markers may include, for example, CD56, NKp30, CD57, GITR, and / or TIGIT. In some embodiments, the expansion cell population of γδT cells (particularly Vδ1T cells) may have a CD56+ cell frequency of more than about 20% (such as more than about 40%, more than about 50%, or more than about 60%). In some embodiments, more than about 60% of the cell population contains γδT cells (particularly Vδ1T cells) expressing CD56. In some embodiments, the expansion cell population of γδT cells (particularly Vδ1T cells) may have a NKp30+ cell frequency of more than about 20% (such as more than about 25%, more than about 30%, or more than about 35%). In some embodiments, more than about 35% of the cell population contains γδT cells expressing NKp30. In some embodiments, the expanded cell population of γδT cells (particularly Vδ1T cells) may have a CD57+ cell frequency of more than about 20% (such as more than about 30%, more than about 40%, or more than about 50%). In some embodiments, more than about 50% of the cell population contains γδT cells expressing CD57. In some embodiments, the expanded cell population of γδT cells (particularly Vδ1T cells) may have a GITR+ cell frequency of more than about 20% (such as more than about 30%, more than about 40%, or more than about 50%). In some embodiments, more than about 50% of the cell population contains γδT cells expressing GITR. In some embodiments, the expanded cell population of γδT cells (particularly Vδ1T cells) may have a TIGIT+ cell frequency of more than about 25% (such as more than about 30%, more than about 35%, more than about 40%, or more than about 45%). In some embodiments, more than about 45% of the cell population contains γδT cells expressing GITR.
[0124] In one embodiment, the cell population comprises γδT cells with low (or undetectable) expression of LAG-3, PD-1, and CTLA-4. In some embodiments, less than about 15% of the cell population comprises γδT cells expressing LAG-3, PD-1, or CTLA-4 (i.e., >15% of γδT cells are LAG-3+, PD-1+, or CTLA-4+).
[0125] In some embodiments, the expansion method as provided herein produces an expanded cell population of γδT cells (particularly Vδ1T cells) with low expression of specific markers relative to a reference population (e.g., an isolated population of γδT cells before the expansion step). Such markers may include, for example, CD27. In some embodiments, the expanded cell population of γδT cells (particularly Vδ1T cells) may have a CD27+ cell frequency of less than about 90% (such as less than about 85%, less than about 80%, or less than about 75%). In certain embodiments, the expanded cell population of γδT cells (particularly Vδ1T cells) has a CD27+ cell frequency of less than 75%. In some embodiments, less than about 75% of the cell population comprises γδT cells expressing CD27.
[0126] In one embodiment, the cell population comprises γδT cells with low (or undetectable) expression of LAG-3, PD-1, and CTLA-4. In some embodiments, less than about 15% of the cell population comprises γδT cells expressing LAG-3, PD-1, or CTLA-4 (i.e., having a LAG-3+, PD-1+, or CTLA-4+ cell frequency of less than 15%).
[0127] In one embodiment, the cell population comprises γδ T cells with low (or undetectable) expression of CD62L and CCR7. In some embodiments, less than about 15% of the cell population comprises γδ T cells expressing CD62L or CCR7 (i.e., having a CD62L+ or CCR7+ cell frequency of less than 15%).
[0128] In some aspects, compared with similar engineered cells obtained by standard methods, the γδT cell colonies (such as Vδ1γδT cell colonies) obtained by the methods described herein have increased in vivo cytotoxicity persistence. In some aspects, the γδT cell colonies obtained by the methods described herein can have in vivo cytotoxicity for at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, at least about 14 days, at least about 15 days, at least about 16 days, at least about 17 days, at least about 18 days, at least about 19 days, at least about 20 days or at least about 21 days. In some aspects, the γδT cell colonies (such as Vδ1γδT cell colonies) obtained by the methods described herein can have in vivo cytotoxicity for at least about 7 days. In some aspects, the γδT cell colonies (such as Vδ1γδT cell colonies) obtained by the methods described herein can have in vivo cytotoxicity for at least about 8 days. In some aspects, the γδT cell population (e.g., Vδ1γδT cell population) obtained by the methods described herein can have in vivo cytotoxicity for at least about 9 days. In some aspects, the γδT cell population (e.g., Vδ1γδT cell population) obtained by the methods described herein can have in vivo cytotoxicity for at least about 10 days. In some aspects, the γδT cell population (e.g., Vδ1γδT cell population) obtained by the methods described herein can have in vivo cytotoxicity for at least about 11 days. In some aspects, the γδT cell population (e.g., Vδ1γδT cell population) obtained by the methods described herein can have in vivo cytotoxicity for at least about 12 days. In some aspects, the γδT cell population (e.g., Vδ1γδT cell population) obtained by the methods described herein can have in vivo cytotoxicity for at least about 13 days. In some aspects, the γδT cell population (e.g., Vδ1γδT cell population) obtained by the methods described herein can have in vivo cytotoxicity for at least about 14 days. In some aspects, the γδT cell population (e.g., Vδ1γδT cell population) obtained by the methods described herein can have in vivo cytotoxicity for at least about 15 days. In some aspects, the γδT cell population (e.g., Vδ1γδT cell population) obtained by the methods described herein can have in vivo cytotoxicity for at least about 16 days. In some aspects, the γδT cell population (e.g., Vδ1γδT cell population) obtained by the methods described herein can have in vivo cytotoxicity for at least about 17 days. In some aspects, the γδT cell population (e.g., Vδ1γδT cell population) obtained by the methods described herein can have in vivo cytotoxicity for at least about 18 days. In some aspects, the γδT cell population (e.g., Vδ1γδT cell population) obtained by the methods described herein can have in vivo cytotoxicity for at least about 19 days.In some aspects, the γδT cell populations (e.g., Vδ1γδT cell populations) obtained by the methods described herein can have in vivo cytotoxicity for at least about 20 days. In some aspects, the γδT cell populations (e.g., Vδ1γδT cell populations) obtained by the methods described herein can have in vivo cytotoxicity for at least about 21 days.
[0129] In some aspects, the γδT cell population (such as Vδ1γδT cell population) obtained by the method described herein, although hardly proliferating, can have in vivo cytotoxicity. Although the efficacy of αβT cell therapy depends on T cell proliferation, the γδT cells produced by the method disclosed herein, although with very little proliferation, can have highly effective cytotoxicity. In some aspects, γδT cell population (such as Vδ1γδT cell population) has less than about 15 times, less than about 14 times, less than about 13 times, less than about 12 times, less than about 11 times, less than about 10 times, less than about 9 times, less than about 8 times, less than about 7 times, less than about 6 times, less than about 5 times, less than about 4 times, less than about 3 times or less than about 2 times of proliferation rate. In some aspects, the γδT cell population (such as Vδ1γδT cell population) obtained by the method described herein can have in vivo cytotoxicity for at least 7 days, wherein the γδT cell population (such as Vδ1γδT cell population) has an increase of less than 15 times of proliferation rate in at least 7 days. In some aspects, the γδT cell population (e.g., Vδ1γδT cell population) obtained by the methods described herein can have in vivo cytotoxicity for at least 10 days, wherein the γδT cell population (e.g., Vδ1γδT cell population) has a proliferation rate of less than 15 times increased in at least 10 days. In some aspects, the γδT cell population (e.g., Vδ1γδT cell population) obtained by the methods described herein can have in vivo cytotoxicity for at least 14 days, wherein the γδT cell population (e.g., Vδ1γδT cell population) has a proliferation rate of less than 15 times increased in at least 14 days. In some aspects, the γδT cell population (e.g., Vδ1γδT cell population) obtained by the methods described herein can have in vivo cytotoxicity for at least 18 days, wherein the γδT cell population (e.g., Vδ1γδT cell population) has a proliferation rate of less than 15 times increased in at least 18 days. In some aspects, the γδT cell population (e.g., Vδ1γδT cell population) obtained by the methods described herein is capable of in vivo cytotoxicity for at least 21 days, wherein the γδT cell population (e.g., Vδ1γδT cell population) has a proliferation rate that increases less than 15-fold over at least 21 days.
[0130] In some aspects, the in vivo cytotoxicity is directed to cancer cells. In some aspects, the cancer cells are solid tumors. In some aspects, the cancers include bone cancer, pancreatic cancer, skin cancer, head and neck cancer, skin or intraocular malignant melanoma, lung cancer (e.g., non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC)), uterine cancer, ovarian cancer, rectal cancer, anal cancer, gastric cancer, testicular cancer, uterine cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease (Hodgkin's Disease), non-Hodgkin's lymphoma, esophageal cancer, small intestine cancer, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, chronic or acute leukemia, acute myeloid leukemia (AML) (e.g., relapsed or refractory AML), chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia (ALL), chronic myeloid leukemia, childhood solid tumors, lymphocytic lymphoma, bladder cancer, kidney or ureter cancer, renal pelvis cancer, central nervous system (CNS) neoplasms, primary CNS lymphoma, tumor angiogenesis, spinal cord axis tumors, brain stem gliomas, pituitary adenomas, Kaposi's sarcoma, epidermoid carcinoma, squamous cell carcinoma, T-cell lymphoma, environmentally induced cancers (including cancers induced by asbestos), or any combination thereof. In some aspects, the cancer is locally advanced. In some aspects, the cancer is metastatic. In some aspects, the cancer is refractory. In some aspects, the cancer is recurrent. In some aspects, the cancer is refractory or recurrent after one or more prior anticancer therapies. In some aspects, the one or more prior anticancer therapies comprise standard of care therapy.
[0131] Engineered cells
[0132] The γδ T cells described herein may also be genetically engineered to obtain enhanced therapeutic properties. For example, the cells may be engineered to express exogenous nucleic acids encoding cell surface receptors and / or secreted proteins.
[0133] An example of cell engineering includes CAR-T therapy. This may involve the generation of engineered receptors (such as chimeric antigen receptors or modified T cell receptors) to reprogram T cells to have new specificity, such as specificity for monoclonal antibodies. Engineered receptors can make T cells specific to malignant cells and can therefore be used for cancer immunotherapy. For example, T cells can recognize cancer cells expressing tumor antigens, which are tumor-specific antigens such as tumor-specific antigens not expressed by normal somatic cells from subject tissues, tumor-associated antigens preferentially overexpressed on cancer cells compared to healthy somatic cells, or antigens expressed in stress events (such as oxidative stress, DNA damage, UV radiation, EGF receptor stimulation; or other means for identifying cancer cells and non-cancerous cells). Therefore, CAR-modified T cells can be used, for example, for adoptive T cell therapy in cancer patients.
[0134] According to another aspect of the present invention, there is provided a method for engineering γδT cells, the method comprising the following steps:
[0135] (i) preparing a composition enriched for γδ T cells using the method as described herein;
[0136] (ii) transducing the composition with an exogenous nucleic acid for expression in the γδ T cells; and
[0137] (iii) culturing the transduced composition to expand the engineered γδ T cells.
[0138] It should be understood that the composition is transduced with an exogenous nucleic acid according to step (ii) for expression in γδT cells to produce engineered γδT cells expressing the exogenous nucleic acid. In some embodiments, the exogenous nucleic acid encodes a surface receptor. In another embodiment, the surface receptor is a chimeric antigen receptor (CAR) that recognizes a tumor antigen.
[0139] In one embodiment, the methods described herein include a composition of transducing γδT cells to express relevant surface receptors, such as CARs that recognize tumor antigens. Any such CARs can be used in the present invention, including CARs targeting CD19, mesothelin (MSLN) or other known tumor-associated antigens.
[0140] According to another aspect of the present invention, there is provided a method for engineering γδT cells, the method comprising the following steps:
[0141] (i) preparing a composition enriched for γδ T cells according to the method as described herein;
[0142] (ii) transducing the composition to express a chimeric antigen receptor (CAR); and
[0143] (iii) culturing the transduced composition to expand the engineered γδ T cells.
[0144] Thus, in some embodiments, step (iii) comprises culturing the transduced composition in the presence of feeder cells.
[0145] In certain embodiments, a viral vector is used to transduce the composition. Such viral vectors are known in the art and the skilled person will be able to identify the appropriate viral vector to be used according to the cells to be transduced. In one embodiment, the viral vector is a lentiviral vector or a retroviral vector, such as a gamma retroviral vector. In another embodiment, the viral vector is a gamma retroviral vector, such as a mouse stem cell virus (MSCV) or Moloney Murine Leukaemia Virus (MLV). In another embodiment, the viral vector is pseudotyped with an envelope (e.g., a beta retroviral envelope, such as a baboon endogenous virus (BaEV) or RD114) other than vesicular stomatitis virus-G (VSV-G).
[0146] In some embodiments, 1x10 6 With 1x10 8 TU / ml (such as about 1x10 6 , about 5x10 6 , about 1x10 7 , about 5x10 7 or about 1x10 8 TU / ml) of viral vector for step (ii). In a specific embodiment, 1×10 7 In one embodiment, the step (ii) is carried out using a viral vector having an MOI of 2.5 TU / ml. In another embodiment, the step (ii) is carried out using a viral vector having an MOI of 5. In another embodiment, the step (ii) is carried out using a viral vector having an MOI of 10.
[0147] In one embodiment, the tumor-associated antigen is an antigen associated with a solid tumor. Thus, in some embodiments, the tumor and / or cancer is a solid tumor. Constitutive expression of CD70, a member of the tumor necrosis family, has been described in both hematological and solid cancers, where it increases the survival of tumor cells and regulatory T cells within the tumor microenvironment by signaling through its receptor CD27. Thus, in another embodiment, the solid tumor is CD70. +Tumor. It will be appreciated that CD70 can be used to target engineered γδ T cells to said tumor. Thus, in another embodiment, the tumor-associated antigen is CD70.
[0148] In an alternative embodiment, the tumor-associated antigen is mesothelin (also referred to herein as "MSLN"). Mesothelin is a 40 kDa protein that is expressed in mesothelial cells and overexpressed in several tumors, including mesothelioma, ovarian cancer, pancreatic adenocarcinoma, lung adenocarcinoma, and cholangiocarcinoma. It has therefore been suggested as a tumor marker or tumor-associated antigen that can be targeted in immunotherapy (Hassan et al. Clin. Cancer Res., 2004, 10 (12): 3937-3942). Mesothelin expression in these tumors can promote tumor implantation and peritoneal spread by cell adhesion (Rump et al., Biological Chemistry, 2004, 279 (10): 9190-9198).
[0149] Expanded cell population
[0150] According to one aspect of the present invention, there is provided an expanded γδT cell population obtained by the method described herein. According to another aspect, there is provided an engineered γδT cell population obtained by the method described herein.
[0151] In some embodiments, the expanded / engineered γδT cell population comprises greater than 50% γδT cells, such as greater than 75% γδT cells, particularly greater than 85% γδT cells. In one embodiment, the expanded / engineered population comprises Vδ1 cells, wherein less than 50% of the Vδ1 cells express TIGIT. In one embodiment, the expanded / engineered population comprises Vδ1 cells, wherein more than 50% (such as more than 60%) of the Vδ1 cells express CD27.
[0152] In some aspects, the expanded / engineered γδT cell population comprises less than about 1% αβT cells. In some aspects, the expanded / engineered γδT cell population comprises less than about 1% αβT cells, less than about 0.9% αβT cells, less than about 0.8% αβT cells, less than about 0.7% αβT cells, less than about 0.6% αβT cells, less than about 0.5% αβT cells, less than about 0.4% αβT cells, less than about 0.3% αβT cells, less than about 0.2% αβT cells, less than about 0.1% αβT cells, less than about 0.09% αβT cells, less than about 0.08% αβT cells, less than about 0.07% αβT cells. Cells, less than about 0.06% of αβT cells, less than about 0.05% of αβT cells, less than about 0.04% of αβT cells, less than about 0.05% of αβT cells, less than about 0.04% of αβT cells, less than about 0.03% of αβT cells, less than about 0.02% of αβT cells, less than about 0.01% of αβT cells, less than about 0.009% of αβT cells, less than about 0.008% of αβT cells, less than about 0.007% of αβT cells, less than about 0.006% of αβT cells, less than about 0.005% of αβT cells. In some aspects, the expanded / engineered γδT cell population includes less than about 0.9% of αβT cells. In some aspects, the expanded / engineered γδT cell population includes less than about 0.8% of αβT cells. In some aspects, the expanded / engineered γδT cell population contains less than about 0.7% of αβT cells. In some aspects, the expanded / engineered γδT cell population contains less than about 0.6% of αβT cells. In some aspects, the expanded / engineered γδT cell population contains less than about 0.5% of αβT cells. In some aspects, the expanded / engineered γδT cell population contains less than about 0.4% of αβT cells. In some aspects, the expanded / engineered γδT cell population contains less than about 0.3% of αβT cells. In some aspects, the expanded / engineered γδT cell population contains less than about 0.2% of αβT cells. In some aspects, the expanded / engineered γδT cell population contains less than about 0.1% of αβT cells. In some aspects, the expanded / engineered γδT cell population contains less than about 0.09% of αβT cells. In some aspects, the expanded / engineered γδT cell population contains less than about 0.08% of αβT cells. In some aspects, the expanded / engineered γδ T cell population contains less than about 0.07% αβ T cells. In some aspects, the expanded / engineered γδ T cell population contains less than about 0.06% αβ T cells. In some aspects, the expanded / engineered γδ T cell population contains less than about 0.05% αβ T cells.In some aspects, the expanded / engineered γδT cell population contains less than about 0.04% αβT cells. In some aspects, the expanded / engineered γδT cell population contains less than about 0.03% αβT cells. In some aspects, the expanded / engineered γδT cell population contains less than about 0.02% αβT cells. In some aspects, the expanded / engineered γδT cell population contains less than about 0.01% αβT cells. In some aspects, the expanded / engineered γδT cell population contains αβT cell concentrations below the detection limit.
[0153] The expanded / engineered γδT cell populations obtained by the methods described herein can be used as medicaments, for example, for adoptive T cell therapy. This involves transferring the expanded / engineered population obtained by the method to a patient. The therapy may be autologous, i.e., the γδT cells may be transferred back to the same patient from which they were obtained, or the therapy may be allogeneic, i.e., the γδT cells from one person may be transferred to a different patient. In examples involving allogeneic transfer, the expanded / engineered population may be substantially free of αβT cells. For example, αβT cells may be depleted from the expanded / engineered population using any suitable method known in the art (e.g., by negative selection, e.g., using magnetic beads), for example, after engineering. The treatment method may include: providing a sample obtained from a donor individual; expanding and / or engineering γδT cells as described herein to produce an expanded / engineered population; and administering an expanded / engineered population of γδT cells to a recipient individual.
[0154] In some aspects, compared with similar engineered cells obtained by standard methods, the amplification / engineered γδT cell colonies obtained by the methods described herein have increased in vivo cytotoxic persistence. In some aspects, the amplification / engineered γδT cell colonies obtained by the methods described herein can have in vivo cytotoxicity for at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, at least about 14 days, at least about 15 days, at least about 16 days, at least about 17 days, at least about 18 days, at least about 19 days, at least about 20 days or at least about 21 days. In some aspects, the amplification / engineered γδT cell colonies obtained by the methods described herein can have in vivo cytotoxicity for at least about 7 days. In some aspects, the amplification / engineered γδT cell colonies obtained by the methods described herein can have in vivo cytotoxicity for at least about 8 days. In some aspects, the amplification / engineered γδT cell colonies obtained by the methods described herein can have in vivo cytotoxicity for at least about 9 days. In some aspects, the amplified / engineered γδT cell population obtained by the methods described herein can have in vivo cytotoxicity for at least about 10 days. In some aspects, the amplified / engineered γδT cell population obtained by the methods described herein can have in vivo cytotoxicity for at least about 11 days. In some aspects, the amplified / engineered γδT cell population obtained by the methods described herein can have in vivo cytotoxicity for at least about 12 days. In some aspects, the amplified / engineered γδT cell population obtained by the methods described herein can have in vivo cytotoxicity for at least about 13 days. In some aspects, the amplified / engineered γδT cell population obtained by the methods described herein can have in vivo cytotoxicity for at least about 14 days. In some aspects, the amplified / engineered γδT cell population obtained by the methods described herein can have in vivo cytotoxicity for at least about 15 days. In some aspects, the amplified / engineered γδT cell population obtained by the methods described herein can have in vivo cytotoxicity for at least about 16 days. In some aspects, the amplified / engineered γδT cell population obtained by the methods described herein can have in vivo cytotoxicity for at least about 17 days. In some aspects, the amplified / engineered γδT cell population obtained by the methods described herein can have in vivo cytotoxicity for at least about 18 days. In some aspects, the amplified / engineered γδT cell population obtained by the methods described herein can have in vivo cytotoxicity for at least about 19 days. In some aspects, the amplified / engineered γδT cell population obtained by the methods described herein can have in vivo cytotoxicity for at least about 20 days.In some aspects, the expanded / engineered γδ T cell population obtained by the methods described herein is capable of in vivo cytotoxicity for at least about 21 days.
[0155] In one embodiment, the expanded / engineered γδT cell population obtained by the methods described herein is used to treat cancer. As used herein, "cancer" refers to abnormal growth or differentiation of cells. Typically, the growth and / or life span of cancer cells exceeds and is not coordinated with the normal cells and tissues around it. Cancer can be benign, pre-malignant or malignant. Cancer occurs in a variety of cells and tissues, including the oral cavity (e.g., mouth, tongue, pharynx, etc.), digestive system (e.g., esophagus, stomach, small intestine, colon, rectum, liver, bile duct, gallbladder, pancreas, etc.), respiratory system (e.g., larynx, lungs, bronchi, etc.), bones, joints, skin (e.g., basal cell, squamous cell, meningioma, etc.), breast, reproductive system (e.g., uterus, ovaries, prostate, testicles, etc.), urinary system (e.g., bladder, kidneys, ureters, etc.), eyes, nervous system (e.g., brain, etc.), endocrine system (e.g., thyroid, etc.), and hematopoietic system (e.g., lymphoma, myeloma, leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, etc.).
[0156] In another embodiment, the cancer is a solid malignant tumor (also referred to herein as a solid tumor). Solid tumors can occur in several locations, such as tissues, bones, muscles, and / or organs. It should be understood that solid tumors do not include blood cancers (i.e., hematological cancers). In an alternative embodiment, the cancer is a hematological cancer.
[0157] In some aspects, the cancer comprises bone cancer, pancreatic cancer, skin cancer, head and neck cancer, skin or intraocular malignant melanoma, lung cancer (e.g., non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC)), uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, non-Hodgkin's lymphoma, esophageal cancer, small intestine cancer, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, chronic or acute leukemia, acute Myeloid leukemia (AML), chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia (ALL), chronic myeloid leukemia, childhood solid tumors, lymphocytic lymphoma, bladder cancer, kidney or ureter cancer, renal pelvic cancer, central nervous system (CNS) neoplasms, primary CNS lymphoma, tumor angiogenesis, spinal cord axis tumors, brain stem gliomas, pituitary adenomas, Kaposi's sarcoma, epidermoid carcinoma, squamous cell carcinoma, T-cell lymphoma, environmentally induced cancer (including cancer induced by asbestos), or any combination thereof. In some aspects, cancer is locally advanced. In some aspects, cancer is metastatic. In some aspects, cancer is refractory. In some aspects, cancer is recurrent. In some aspects, cancer is refractory or recurrent after one or more prior anticancer therapies. In some aspects, one or more prior anticancer therapies include the standard of care therapy.
[0158] The patient or subject to be treated is preferably a human cancer patient (e.g., a human cancer patient being treated for a solid tumor) or a viral infection patient (e.g., a CMV-infected or HIV-infected patient). In some cases, the patient has and / or is being treated for a solid tumor. Because tissue-resident Vδ1 T cells typically reside in non-hematopoietic tissues, they are also more likely to localize to and remain within tumor masses than their systemic blood-resident counterparts, and adoptive transfer of these cells may be more effective in targeting solid tumors and potentially other non-hematopoietic tissue-related immunopathologies.
[0159] Because γδ T cells are non-MHC restricted, they do not recognize the host into which they are transferred as foreign, which means that they are unlikely to cause graft-versus-host disease. This means that they can be used "off the shelf" and transferred into any recipient, for example for allogeneic adoptive T cell therapy.
[0160] The γδ T cells obtained by the methods described herein express NKG2D and respond to NKG2D ligands (e.g., MICA), which are strongly associated with malignant tumors. They also express cytotoxic patterns in the absence of any activation and may therefore be effective in killing tumor cells. For example, the expanded / engineered γδ T cells obtained as described herein may express one or more, preferably all, of IFN-γ, TNF-α, GM-CSF, CCL4, IL-13, granulysin, granzymes A and B, and perforin in the absence of any activation. IL-17A may not be expressed.
[0161] The expanded / engineered γδ T cells obtained by the methods described herein may be suitable as "off-the-shelf" immunotherapeutic agents. These cells have intrinsic-like killing effects, are not MHC-restricted and exhibit improved intratumoral localization and / or retention compared to other T cells.
[0162] In some embodiments, a method of treating an individual with a solid tumor in a non-hematopoietic tissue may include: expanding / engineering γδT cells from a sample of an individual as described herein to produce an expanded / engineered population; and administering the expanded / engineered population of γδT cells to the individual. In alternative embodiments, the method of treatment includes expanding / engineering γδT cells from a sample of a different individual as described herein to produce an expanded / engineered population; and administering the expanded / engineered population of γδT cells to the individual with a solid tumor. In one embodiment, the amount of expanded / engineered γδT cells administered to the individual is a therapeutically effective amount.
[0163] In other embodiments, the treatment methods and / or therapeutically effective amounts include those disclosed in WO2020095058 or WO2020095059, the contents of which are incorporated herein in their entirety.
[0164] The pharmaceutical composition may include a combination of expanded and / or engineered γδT cells as described herein and one or more pharmaceutically or physiologically acceptable carriers, diluents, or excipients. Such compositions may include buffers such as neutral buffered saline, phosphate buffered saline, etc.; carbohydrates such as glucose, mannose, sucrose or dextran, mannitol; proteins; polypeptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide); and preservatives. Cryopreservation solutions that can be used in the pharmaceutical compositions of the present invention include, for example, DMSO. The composition may be formulated, for example, for intravenous administration.
[0165] Therefore, according to another aspect of the present invention, there is provided a pharmaceutical composition comprising an expanded γδ T cell population or an engineered γδ T cell population as described herein.
[0166] In one embodiment, the pharmaceutical composition is substantially free of (eg, is free of) detectable levels of contaminants, such as endotoxins or Mycoplasma.
[0167] According to another aspect of the present invention, an expanded γδT cell population, an engineered γδT cell population or a pharmaceutical composition as described herein for use as a medicament is provided. In another aspect, an expanded γδT cell population, an engineered γδT cell population or a pharmaceutical composition as described herein for use in treating cancer is provided. In another embodiment, the cancer is a solid tumor.
[0168] It should be understood that all embodiments described herein are applicable to all aspects of the invention.
[0169] As used herein, the term "about" includes up to and including 10% greater than the specified value and up to and including 10% less than the specified value, appropriately up to and including 5% greater than the specified value and up to and including 5% less than the specified value, especially the specified value. The term "between" includes the values of the specified boundaries.
[0170] Unless otherwise indicated, the practice of the present disclosure will employ conventional techniques of cell biology, cell culture, molecular biology, transgenesis biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are fully explained in the literature. See, e.g., Sambrook et al., eds. (1989) Molecular Cloning A Laboratory Manual (2nd ed.; Cold Spring Harbor Laboratory Press); Sambrook et al., eds. (1992) Molecular Cloning: A Laboratory Manual, (Cold Springs Harbor Laboratory, NY); DN Glover, ed. (1985) DNA Cloning, Vol. I and Vol. II; Gait, ed. (1984) Oligonucleotide Synthesis; Mullis et al., U.S. Pat. No. 4,683,195; Hames and Higgins, eds. (1984) Nucleic Acid Hybridization; Hames and Higgins, eds. (1984) Transcription And Translation; Freshney (1987) Culture Of Animal Cells (Alan R. Liss, Inc.); Immobilized Cells And Enzymes (IRL Press) (1986); Perbal (1984) A Practical Guide To Molecular Cloning; the treatise,Methods In Enzymology (Academic Press, Inc., NY); Miller and Calos (1987) Gene Transfer Vectors For Mammalian Cells, (Cold Spring Harbor Laboratory); Wu et al. (1987) Methods In Enzymology, Volumes 154 and 155; Mayer and Walker (1987) Immunochemical Methods In Cell And Molecular Biology (Academic Press, London); Weir and Blackwell (1986) Handbook Of Experimental Immunology, Volumes I to IV; Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1986)); Crooke, Antisense drug Technology: Principles, Strategies and Applications, 2nd edition CRC Press (2007) and Ausubel et al. (1989) Current Protocols in Molecular Biology (John Wiley and Sons, Baltimore, Md.). .
[0171] All references cited above and all references cited herein are incorporated by reference in their entirety.
[0172] Certain aspects and embodiments of the invention will now be illustrated by means of the following examples and with reference to the drawings described above.
[0173] Example
[0174] Example 1. Materials and methods
[0175] Cell culture
[0176] According to the following description and as Figure 1 The methods outlined in generate cultures enriched for Vδ1+γδ T cells.
[0177] Method 1: Vδ1+γδT cells were generated from αβ-TCR+ depleted and peripheral blood mononuclear cells using serum-free medium (CTS OpTmizer, Thermo Fisher) supplemented with 2.5% pooled allogeneic plasma (Octaplas, Octapharma) and Glutamax (ThermoFisher). Isolated cells were inoculated in the presence of recombinant IL-4 (Miltenyi), IL-1β (Miltenyi), IL-21 (CellGenix), IFNγ (Bio-Techne) and soluble anti-CD3 (clone OKT3) antibodies (Biolegend). After setting, the culture was incubated in a humidified incubator at 37°C and 5% CO2. The culture medium was supplemented with fresh IL-21 (39 ng / ml) (CellGenix) and IL-15 (21 ng / ml) (Bio-Techne) on day 7 and IL-15 (100 ng / ml) (Bio-Techne) on day 11. Cells were harvested after 14 days of culture and cryopreserved as mixed populations in Cryostor5 (STEMCELL Technologies).
[0178] Method 2: Vδ1+γδT cells were generated from αβ-TCR+ depleted peripheral blood mononuclear cells using serum-free culture medium (CTS OpTmizer, Thermo Fisher) supplemented with 2.5% pooled allogeneic plasma (Octaplas, Octaphar ma) and Glutamax (ThermoFisher). The isolated cells were inoculated in the presence of recombinant IL-15 (100ng / ml) (Bio-Techne) and soluble anti-CD3 (clone OKT3) antibodies (Biolegend) and in the absence of IL-21 (e.g., in the absence of IL-21). After setting, the culture was incubated in a humidified incubator at 37°C and 5% CO2. Fresh IL-15 (100ng / ml) (Bio-Techne) was supplied to the amplified cells. The cells were harvested after 14 days of culture and cryopreserved as a mixed population in Cryostor5 (STE MCELL Technologies).
[0179] Flow cytometric assessment of cell purity and surface phenotype
[0180] Standard characterization: using MACSQuant16 or BD FACSLyric TM Immunophenotyping was performed by flow cytometry. The same protocol was used to characterize the cell products at harvest and after cryopreservation. TMDead cells were excluded using a fixable aqueous dead cell stain kit (Invitrogen). Cells were analyzed for expression of surface markers using BV421-CD27, BV421-DNAM-1, BV605-PD-1, FITC-mesothelin, PE-NKG2D, PE-NKp30, PE-Cy7-CD56, PE-Cy7-TIGIT, APC-TCRγδ, APC-Cy7-Vδ1 antibodies available from Miltenyi, BioLegend, and ACROBiosystems.
[0181] In-depth characterization: using Biolegend's LEGENDScreen TM The Human PE Kit (#700007) was used for in-depth immunophenotyping. This in-depth characterization involved studying the cell surface expression of 361 markers in cell products produced according to Method 1 or 2.
[0182] Quantification of secreted factors :
[0183] Secreted proteins were quantified after cryopreservation. Briefly, Vδ1+γδ T cell products were thawed and co-cultured with OVCAR3 attached tumor targets overnight. Next, supernatants were collected and quantified using 65-Plex Human ProcartaPlex according to the manufacturer's instructions. TM Kit (Catalog No.: EPX650-10065-901). The labeled samples were analyzed using the FLEXMAP 3D platform. This analysis allows for the simultaneous detection and quantification of 65 secreted proteins, including cytokines and chemokines, during co-culture with target cells. Effector alone was used as a control.
[0184] Transduction with a gamma-retroviral vector encoding an anti-MSLN chimeric antigen receptor
[0185] Cells were expanded according to method 1 or 2 and transduced with a γ-retroviral vector encoding mesothelin (MSLN) targeting a chimeric antigen receptor in the presence of fibronectin (20 μg / mL). The viral vector was mixed with immune cells diluted overnight in a CTS OpTmizer at 37°C. Transduction efficiency was determined by flow cytometry four to nine days after transduction.
[0186] Thawing of cryopreserved cell products
[0187] Frozen cryovials were thawed in a 37°C water bath and added to pre-warmed OpTmizer containing 2.5% allogeneic plasma. Cells were centrifuged at 300 g for 7 minutes, counted and assessed for viability, and then plated at 2×106 The cells were resuspended for phenotyping and downstream analysis.
[0188] Cytotoxicity assay
[0189] The expanded cells were co-cultured with adherent tumor targets (e.g., ovarian adenocarcinoma cell line OvCAR3) at various effector to target ratios, some of which expressed firefly luciferase. Target cells in the absence of effectors served as controls (Ctrl). Maximum lysis was determined using target cells treated with staurosporine. After 20 hours, ONE-Glo TM Luciferase Assay System Kit (Promega) or Luminescent cell viability assay (Promega) was used to assess the quantification of target viability. Luminescence was measured on a Biotek Synergy H4 plate reader.
[0190] Repeat antigen stimulation assay
[0191] Cryopreserved Vδ1+γδT cell products were thawed and co-cultured with GFP-expressing adherent tumor targets (e.g., lung cancer cell line A549-Meso+) in the presence of cytokines at an effector-to-target ratio of 2.5 effectors per target. Live cell analysis system (Sartorius) was incubated at 37°C and 5% CO2. Vδ1+γδ T cell production was stimulated by adding fresh tumor targets to the culture every 3-4 days. The percentage of GFP was used as a measure of residual tumor targets at each time point in the analysis. To calculate Vδ1+γδ fold expansion, cells were counted at each time point and flow cytometry was performed to determine Vδ1+γδ enrichment.
[0192] Example 2. Comparison of cell products
[0193] The method described in Example 1 was used and Figure 1 αβ-TCR+ depleted peripheral blood mononuclear cells were expanded according to the methods outlined in 1 or 2. The expanded cell products were then analyzed and compared.
[0194] The cell yield at harvest was Figure 2 Growing cells according to Method 2 produced cell yields similar to (or slightly lower than) Method 1. Method 2 produced reduced inter-supplier yield variability.
[0195] Immune cell composition was analyzed by flow cytometry ( Figure 3 Both expansion methods produced pure γδ T cell products that were highly enriched in Vδ1 T cells (>50%).
[0196] Vδ1 T cells generated using method 2 upregulated CD56, a major marker of cell products produced by this method. Representative flow cytometry plots are shown in Figure 2. Figure 4 As shown in . Vδ1 T cells expanded by method 2 presented unique cell surface marker expression with significantly lower CD27 expression and higher CD56, NKp30, CD57, GITR and TIGIT expression, which is consistent with a more effector-like phenotype. Markers such as LAG-3, PD-1 and CTLA-4 associated with exhaustion remained low or undetectable ( Figure 5 ). In addition, expansion of cells according to method 2 altered the expression of various chemokine receptors ( Figure 6 ). While CD62L and CCR7 (two markers associated with lymph node retention) were significantly downregulated, CCR6 (a marker associated with peripheral retention) was significantly upregulated.
[0197] The cell products generated by methods 1 and 2 were deeply phenotyped using LegendScreen technology, which allowed the simultaneous analysis of 364 cell surface markers. Flow cytometry results were analyzed using ANOVA and presented as volcano plots. The analysis revealed surface markers that were significantly differentially expressed between the two amplification methods ( Fig. 7A ). Each individual point in the volcano plot represents an individual cell surface marker analyzed. The higher the position of the point in the y-axis, the greater the significance of the differential expression of the marker between cells generated by method 2 when compared to method 1. The more dispersed the position of the point in the x-axis (above or below 0), the greater the fold exchange expression of the individual marker between cells generated by method 2 when compared to method 1. The cell surface markers that were significantly changed by growing cells according to method 2 when compared to method 1 were mainly involved in co-activation, adhesion / migration / retention, and immune coordination signaling pathways ( Figure 7B ). The most relevant and significantly altered markers are listed in a tabular format in Table 1 below. In summary, the altered marker expression contributed to the unique functionality of cells generated by Method 2 when compared to Method 1.
[0198] Table 1. Relevant and significantly changed markers
[0199]
[0200] Cell products generated by methods 1 and 2 were analyzed for factor secretion using Luminex technology, which allowed for the simultaneous detection and quantification of 65 proteins per sample. Principal component analysis (PCA) was performed ( Fig. 8A) to measure differences in soluble factor secretion between samples prepared using Method 1 and Method 2. PCA analysis showed that samples produced with Method 2 (black dots) clustered separately from samples produced by Method 1 (white dots), revealing a unique soluble factor secretion profile of γδ T cell products produced by Method 2 when compared to Method 1. Vδ1 T cells expanded by Method 2 exhibited a significant increase in secretion of effector cytokines such as IFNγ and GM-CSF compared to Method 1 ( Figure 8B In addition, method 2 resulted in a significant increase in the secretion of chemokines such as CXCL9 and CXCL10 and an almost significant increase in CXCL11, CCL4, CCL7, and CCL20 ( Figure 8C ).
[0201] Example 3. Functionality of cell products after storage
[0202] The functionality of the cells was also investigated. The frozen cell products were thawed according to Example 1. The total cell recovery and viability after cryopreservation were similar between the cell products produced using Method 1 or 2. However, the cells produced according to Method 2 exhibited slightly higher viability after cryopreservation ( Fig. 9 Importantly, the immune cell composition and cell surface phenotype of the cell products were preserved after cryopreservation (data not shown).
[0203] The cytotoxicity of the cell products after cryopreservation was also investigated. Relative to cells produced using Method 1, the cell products produced according to Method 2 were significantly more cytotoxic against a broad range of solid tumor cancer cell lines over a range of effector to target ratios ( Fig.10 ).
[0204] Example 4. Functionality of cell products after transduction
[0205] The expanded cells were transduced with γ-retroviral vectors as described in Example 1 and gene transfer efficiency was determined by flow cytometry. Chimeric antigen receptor expression was identical between cells expanded by either method 1 or 2, indicating that modifying the expansion method did not alter the permissiveness of Vδ1 T cells to γ-retroviral transduction ( Fig.11A ).exist Fig. 11B Representative flow cytometric characterization of CAR expression in cells transduced and expanded by method 1 or 2 can be seen in .
[0206] In addition, the functionality of the engineered cell products was investigated in an overnight cytotoxicity assay ( Fig.12) and repeated tumor stimulation in two different models using OVCAR3 and A549-Meso tumor cell lines (Figure 13). In the case of overnight cytotoxicity analysis, CAR-transduced cells showed similar cytotoxicity regardless of the method used to expand them. CAR transduction greatly enhanced the overnight cytotoxicity of the cell product amplified according to method 1 ( Fig.12 However, in the case of repeated antigen stimulation (RAS) analysis at day 21, where our cell products were challenged with tumor every 3 to 4 days, only cells transduced with CARs expanded with method 2 were able to control tumor growth until day 21 in all models used ( Fig.13A Additionally, the superior tumor control exhibited by products amplified by Method 2 during the analysis period may have significantly lower fold expansions when compared to products from cells grown using Method 1 ( Fig. 13B ). This suggests that the cell products grown using Method 2 are more capable of multiple rounds of effective serial killing and control of tumors over time. Overall, these observations emphasize that the inherent cytotoxic function conferred to Vδ1 T cells against tumor targets works synergistically with the engineering strategy. Therefore, the Method 2 culture method enhances the functionality of γδ cell products to a greater extent and independently of engineering.
[0207] Example 5. Analysis of IL-15 concentration
[0208] Vδ1+γδT cells will be generated from αβ-TCR+ depleted peripheral blood mononuclear cells as described in Example 1. The isolated cells will be inoculated in the presence of various concentrations of recombinant IL-15 and soluble anti-CD3 (clone OKT3) antibodies (Biolegend) in the absence of IL-21 (e.g., in the absence of IL-21). After setting, the culture will be incubated in a humidified incubator at 37°C and 5% CO2. Various concentrations of fresh IL-15 will be supplied to the expanded cells. Cells will be harvested after 14 days of culture and frozen for further analysis. The IL-15 concentrations tested include, but are not limited to, about 5 ng / mL to about 150 ng / mL (e.g., 5 ng / mL, 10 ng / mL, 15 ng / mL, 20 ng / mL, 25 ng / mL, 30 ng / mL, 35 ng / mL, 40 ng / mL, 45 ng / mL, 50 ng / mL, 60 ng / mL, 70 ng / mL, 80 ng / mL, 90 ng / mL, 100 ng / mL, 110 ng / mL, 120 ng / mL, 130 ng / mL, 140 ng / mL, and 150 ng / mL).
Claims
1. A method for expanding γδT cells, wherein the method comprises the following steps: (1) preparing a composition enriched in γδ T cells by depleting αβ T cells from a sample obtained from a subject containing γδ T cells; (2) culturing the composition enriched in γδ T cells in the presence of: (i) an anti-CD3 antibody or a fragment thereof; as well as (ii) interleukin-15 (IL-15) in the absence of interleukin-4 (IL-4) from the first day of said culture; and (3) Isolating a cell population cultured from the composition. The method according to claim 1 , wherein the sample is a hematopoietic system sample or a fraction thereof.
3. The method according to claim 2, wherein the sample is selected from peripheral blood, umbilical cord blood, lymphoid tissue, thymus, bone marrow, spleen, lymph node tissue or fractions thereof, in particular peripheral blood or fractions thereof.
4. The method according to claim 3, wherein the sample consists of peripheral blood mononuclear cells (PBMC) or low-density mononuclear cells (LDMC). The method of claim 1 , wherein the sample is non-hematopoietic tissue.
6. The method according to any one of claims 1 to 5, wherein the subject is a human.
7. The method according to any one of claims 1 to 6, wherein the method comprises culturing the composition for 7 to 21 days.
8. The method of claim 7, wherein the method comprises culturing the composition for about 10, 11, 12, 13 or 14 days.
9. The method according to any one of claims 1 to 8, wherein the anti-CD3 antibody is OKT3.
10. The method according to any one of claims 1 to 9, wherein the population of expanded γδ T cells provides at least 5-fold, particularly at least 10-fold, in particular at least 20-fold the number of γδ T cells.
11. The method according to any one of claims 1 to 10, wherein at least 50% of the expanded γδ T cells present in the cell population express CD56.
12. The method according to any one of claims 1 to 11, wherein the cell population comprises γδ T cells expressing NKp30, CD57, GITR, TIGIT, CCR6, CCR2, CCR5 and / or CXCR6.
13. The method according to any one of claims 1 to 12, wherein the γδ T cells are derived from a single donor.
14. The method according to any one of claims 1 to 12, wherein the γδ T cells are derived from a plurality of donors.
15. The method according to any one of claims 1 to 14, wherein the method comprises freezing the expanded γδ T cells.
16. A method for engineering γδ T cells, the method comprising the following steps: (i) preparing a composition enriched in γδ T cells using the method according to any one of claims 1 to 15; (ii) transducing the composition with an exogenous nucleic acid for expression in the γδ T cells; and (iii) culturing the transduced composition to expand the engineered γδ T cells.
17. The method of claim 16, wherein the exogenous nucleic acid encodes a chimeric antigen receptor (CAR) that recognizes a tumor antigen.
18. The method of claim 17, wherein the tumor antigen is a tumor-specific antigen that is not expressed by normal somatic cells from a tissue of the subject.
19. The method of claim 17 or claim 18, wherein the tumor antigen is a tumor-associated antigen that is preferentially overexpressed on cancer cells compared to healthy somatic cells.
20. The method according to any one of claims 17 to 19, wherein the tumor antigen is an antigen expressed under stress events such as oxidative stress, DNA damage, UV radiation, EGF receptor stimulation, etc.
21. The method according to any one of claims 17 to 20, wherein the tumor antigen is an antigen associated with a solid tumor.
22. The method according to any one of claims 16 to 21, wherein the composition is transduced using a viral vector, such as a retroviral vector, such as a gammaretroviral vector or a lentiviral vector.
23. The method of claim 22, wherein the viral vector is a gammaretroviral vector, such as murine stem cell virus (MSCV) or Moloney murine leukemia virus (MLV).
24. A method according to claim 22 or claim 23, wherein the viral vector is pseudotyped with an envelope other than vesicular stomatitis virus-G (VSV-G), for example a beta-retroviral envelope, such as baboon endogenous virus (BaEV) or RD114.
25. The method of any one of claims 16 to 24, wherein step (iii) comprises culturing the transduced composition in the absence of feeder cells.
26. The method of any one of claims 16 to 24, wherein step (iii) comprises culturing the transduced composition in the presence of feeder cells.
27. An expanded population of γδ T cells obtainable by, such as obtained by, the method of any one of claims 1 to 26.
28. A pharmaceutical composition comprising the expanded γδ T cell population according to claim 27.
29. The expanded γδ T cell population according to claim 27 or the pharmaceutical composition according to claim 28, for use as a medicament.
30. The expanded γδ T cell population according to claim 27 or the pharmaceutical composition according to claim 28, for use in treating cancer.
31. The expanded γδ T cell population or pharmaceutical composition for use according to claim 30, wherein the cancer is a solid tumor.
32. The expanded γδT cell population according to claim 27 or the pharmaceutical composition according to claim 28, wherein the expanded γδT cells are capable of sustained cytotoxicity for at least about 7 days, at least about 8 days, at least about 9 days, at least about 10 days, at least about 11 days, at least about 12 days, at least about 13 days, at least about 14 days, at least about 15 days, at least about 16 days, at least about 17 days, at least about 18 days, at least about 19 days, at least about 20 days, or at least about 21 days.
33. The expanded γδ T cell population of claim 27 or the pharmaceutical composition of claim 28, wherein the expanded γδ T cells are capable of sustained cytotoxicity for at least about 14 days.
